Medical University of South Carolina

MEDICA
MUSC Theses and Dissertations
1998

Clear Cell Sarcoma of the Kidney and Congenital Mesoblastic
Nephroma: Cellular and Molecular Characterization of Primary
Tumors, Tumor Cell Lines, and Nude Mouse Xenografts Delineate
Wilms' Tumor-Distinct Histopathogenetic Properties
Noel Anderson Brownlee
Medical University of South Carolina

Follow this and additional works at: https://medica-musc.researchcommons.org/theses

Recommended Citation
Brownlee, Noel Anderson, "Clear Cell Sarcoma of the Kidney and Congenital Mesoblastic Nephroma:
Cellular and Molecular Characterization of Primary Tumors, Tumor Cell Lines, and Nude Mouse
Xenografts Delineate Wilms' Tumor-Distinct Histopathogenetic Properties" (1998). MUSC Theses and
Dissertations. 174.
https://medica-musc.researchcommons.org/theses/174

This Dissertation is brought to you for free and open access by MEDICA. It has been accepted for inclusion in
MUSC Theses and Dissertations by an authorized administrator of MEDICA. For more information, please contact
medica@musc.edu.

Clear Cell Sarcoma of the Kidney and Congenital Mesoblastic Nephroma: Cellular and
Molecular Characterization of Primary Tumors, Tumor Cell Lines, and Nude Mouse Xenografts
Delineate Wilms' Tumor-Distinct Histopathogenetic Properties

Noel Anderson Brownlee

A dissertation submitted to the faculty of the Medical University of South Carolina in
partial fulfillment for the degree of Doctor of Philosophy in the College of Graduate Studies

Medical University of South Carolina
Department of Pathology and Laboratory Medicine
1998

11

Acknowledgments

I would like to first thank my parents for their support, encouragement, and patience
during my tenure at the Medical University of South Carolina. Without these, I would not
have been able pursue my interests in pathology.
Dr. Debra Hazen-Martin, my mentor and chairperson of my advisory committee
deserves many thanks for listening to my concerns over the years. She has consistently
offered invaluable advice and assistance in many aspects of my training. Because of her
excellent teaching skills, I was able to learn many aspects of tissue culture, electron
microscopy, and histochemistry. I also appreciate her commitment to improving graduate
education in experimental pathology and for encouraging my future endeavors into this field.
More than anything, she will always be valued as a good friend.
I would like to thank Dr. Gian Re for his patience and dedication to teaching me the
ropes of the molecular biology laboratory. Dr. Re is also an invaluable friend who has
offered me sound advice regarding subjects both on and off of campus. Dr. Re is also a
natural teacher whose expertise is not always duly recognized; he has a lot to offer to any
student who becomes a part of this department.
Dr. Garvin has been an invaluable committee member. He has provided me with
specimens that have enabled me to initiate cell cultures for all of my studies on clear cell
sarcoma of the kidney and congenital mesoblastic nephroma. I would especially like to thank
him for remaining on my committee even after he relocated to Wake Forest University
School of Medicine and taking the time out of his busy schedule to attend all of my
committee meetings.
I would like to thank Drs. Willingham, Gattoni-Celli, and Fernandes for all of their
helpful input regarding my project, particularly in the realm of cell cycle analysis and
evaluation of apoptosis in CMN and CCSK. I also would like to thank Dr. Allen for his
helpful input regarding gel electrophoresis. I would especially like to thank Dr. Willingham
for remaining on my committee and making the trips from Winston-Salem to Charleston
over the past year.
Carol Moskos, Sadie Green, and Margaret Romano deserve many thanks not only for
their teclmical expertise, but also for their valued friendship.Carol worked very hard in trying
to help me finish my transmission and seaMing electron micrographs, Sadie assisted me
greatly in maintaining my cell lines in my absence, and Margaret always did a nice job in
preparing, cutting, and staining tissue in the histology laboratory. I would also like to thank
Linda McCarson for her excellent Word Processing pointers regarding the preparation of this
dissertation.

111

Table of Contents
Acknowledgments.
Table of Contents.
List of Tables.
List of Figures.
List of Abbreviations.
Abstract.

.11

...

.111

.VI
.VB
.IX
.XI

Chapter 1: Introduction
1.
II

General Introduction. .
Historical Background.
1. Genetic Etiology of Wilms' Tumor:Initiating Factors.
2. p53 Signal Transduction: Cell Cycle Control and Apoptosis.
3. p53 and Anaplastic Progression in Wilms' Tumor.
4. Genetic Basis of Kidney Development with Implications for16
Pediatric Renal Tumor Histogenesis.
5. All-trans Retinoic Acid Induced Differentiation of Tumor Cells ..
6. Congenital Mesoblastic Nephroma: Molecular Biology and 265
Histogenesis.
7. Clear Cell Sarcoma of the Kidney: Molecular Biology and
Histogenesis.

Chapter 2: Materials and Methods
I.
Tumor Specimens.
II
Chemicals.
III.
Nude Mouse Heterotransplantation. .
IV.
Tumor and Heterotransplant Tissue Fixation, Processing, and
Hematoxylin and Eosin Staining.
Transmission Electron Microscopic Evaluation of Tumor Cell Cultures.
V.
VI.
Scanning Electron Microscopic Evaluation of Tumor Cell Cultures.
VII.
Initiation of Tumor Cell Culture.
VIII. Cis-diamminedichloroplatinum (II) DNA Damage
Response Assay.
IX.
All-trans Retinoic Acid Induced Cell Differentiation Assay.
X.
Immunocytochemistry Using Peroxidase Labelled Secondary Antibodies .
XI.
Immunofluorescence Cytochemistry.
Flow Cytometry: Cell Cycle Analysis.
XII.
XIII. 8DS-Polyacrylamide Gel Electrophoresis and Western Blotting.
XIV. RNA Extraction-Agaraose Gel Electrophoresis-Northern Blotting..
XV. cDNA Probe Labelling and Nucleic Acid Hybridization.
XVI. p53 Polymerase Chain Reaction-Single Stranded Conformation
Polymorphism and DNA Sequencing.

.2
.3
.3
.11
.14
.17
.22
.24
.26

.41
.41
.42
.42
.43
.44
.44
.47
.47
.48
.49
.50
.51
.52
.53
.55

IV

Chapter 3: Morphologic and Molecular Characterization of an In Vitro and In Vivo
Model for the Study of Clear Cell Sarcoma of the Kidney and Congenital Mesoblastic
Nephroma
I.
Introduction. .
.58
II.
Results.
.61
1. In Vitro Characteristics ofCCSK and CMN.
.61
2. Light and Electron Microscopic Analysis of CCSK and CMN
.61
Nude Mouse Xenografts.
3. Immunofluorescent Cytochemical Analysis of Intermediate Filament
.63
Proteins in CCSK and CMN Cells.
4. WT-l and IGF-2 Northern Analysis.
.64
III.
Discussion.
.65

Chapter 4: Characterization of the p53 Signal Transduction Pathway in Clear Cell
Sarcoma ortbe Kidney, Congenital Mesoblastic Nephroma, and Anaplastic
Wilms'Tumor
I.
II.

Introduction. .
Results.
1. p53 Immunochemistry, SSCP, and DNA Sequencing Analysis..
2. mRNA Induction in Cisplatin Treated Tumor Cells.
3. Stabilization of p53 Protein in Cisplatin Treated Cells.
4. Flow Cytometric Evaluation of G 1 Cell Cycle Arrest.
5. Steady-state mRNA Expression ofp53, p21, MDM-2, and MDR-l
in CCSK and CMN Primary Tumors.
III. Discussion.

.87
.91
.91
.92
.94
.95
.95
.97

Chapter 5: Steady-state and Retinoic Acid Induced Gene Expression Analysis of Clear
Cell Sarcoma of the Kidney and Congenital Mesoblastic Nephroma: A Model of Tumor
Histogenesis
I.
II.

Introduction. .
Results.
1. Expression of Genes Involved in Normal Nephrogenesis in
CCSK and CMN Primary Tumors.
2. Phase Contrast Microscopy of all-trans Retinoic Acid Treated
CCSK and CMN Tumor Cells.

.132
.138

.138
.138

v

Chapter 5{continued)

III.

3. Transmission and Scanning Electron Microscopic Analysis of
all-trans Retinoic Acid Treated CCSK and CMN Cell Cultures.
4. All-trans Retinoic Acid Induced Gene Expression Alterations in
CCSK and CMN Cells.
Discussion.

.139

.140
.142

Chapter 6: Summary and Conclusions.

.172

Chapter 7: List of References.

.178

VI

List of Tables

CHAPTER!
Table 1.
Table 2.

.38
.39

CHAPTER 2
No Tables

CHAPTER 3
Table 1.

.85

Table 1.
Table 2.

.129
.130

CHAPTER 4

CHAPTERS

No Tables

CHAPTER 6
No Tables
CHAPTER 7
No Tables

Vll

List of Figures
CHAPTER!

Figure 1.
Figure 2.
Figure 3.
Figure 4.

.30
.32
.34
.36

CHAPTER 2
No Figures

CHAPTER 3
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.
Figure 7.
Figure 8.

.69
.71
.73
.75
.77
.79
.81
.83

Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.
Figure 7.
Figure 8.
Figure 9.
Figure 10.
Figure 11.
Figure 12.
Figure 13.
Figure 14.

.101
.103
.105
.107
.109
.111
.113
.115
.117
.119
.121
.123
.125
.127

Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.

.149
.151
.153
.155
.157

CHAPTER 4

CHAPTERS

VIn

CHAPTER 5 (continued)
Figure 6.
Figure 7.
Figure 8.
Figure 9.
Figure 10.
Figure 11.

CHAPTER 6
No Figures

CHAPTER 7

No Figures

.159
.161
.163
.165
.167
.169

IX

LIST OF ABBREVIATIONS

ABC

Avidin-Biotin-horseradish peroxidase complex

AEI/AE3

monoclonal antibody to cytokeratin intermediate filaments

atRA

all-trans retinoic acid

aWT

anaplastic Wilms' tumor

Bax

pro-apoptotic gene

Bcl-2

B-celllymphoma-2 gene

Bcl-xL

B-celllymphoma-x-Iong gene

BF-2

winged-helix transcription factor specific to developing renal stroma

BP2

insulin-like growth factor binding protein 2

CCSK

clear cell sarcoma of the kidney

CMN

congenital mesoblastic nephroma

DAB

3,3'- diaminobenzidine

dCTP

deoxycytosine triphosphate

DMEM

Dulbecco's modified Eagle's Medium

EDTA

ethylenediaminetetracetic acid

EGR

early growth response

F12

Ham's F12 Medium

FCS

fetal calf serum

GAPD

glyceraldehyde phosphate dehydrogenase

HBSS

Hank's balanced salt solution

IGF-IR

type I insulin-like growth factor receptor

IGF-2

insulin-like growth factor 2

kb

kilobase

MDM-2

murine double minute-2 gene

NBF

neutral buffered formalin

OCT

frozen tissue embedding compound

p21

cyclin-dependent kinase inhibitor p21 waf-llcip-l

x

p53

tumor suppressor protein 53

PBS

phosphate buffered saline

peR

polymerase chain reaction

RAR-a

retinoic acid receptor alpha

RTK

rhabdoid tumor of the kidney

SDS

sodium dodecyl sulfate

SEM

scanning electron microscopy

SMA

smooth muscle actin

sse

standard saline citrate

SSCP

single-stranded conformation polymorphism analysis

TBE

tris borate EDTA

TEM

transmission electron microscopy

TEMED

N ,N ,N' ,N' -tetramethylethylenediamine

Xl

ABSTRACT

NOEL ANDERSON BROWNLEE. Clear Cell Sarcoma of the Kidney and Congenital
Mesoblastic Nephroma: Cellular and Molecular Characterization of Primary Tumors, Tumor
Cell Lines~ and Nude Mouse Xenografts Delineate Wilms' Tumor Distinct Histopathogenetic
Properties. (Under the direction of Dr. DEBRA J. HAZEN-MARTIN)
Clear cell sarcoma of the kidney (CCSK) and Congenital mesoblastic nephroma
(CMN) are both pediatric renal tumors that differ from Wilms' tumor based on their
distinctive histopathologic characteristics and clinical behavior. CCSK is a very malignant
tumor characterized by a propensity for bone metastases, contrasting the relatively benign
course characteristic of the majority of Wilms' tumors. CMN, in contrast, is a tumor of the
newborn usually diagnosed within the first three months of life that is generally cured with
surgery alone. To investigate further the cellular and molecular relationships of CCSK,
CMN, and Wilms' tumor, a nude mouse xenograft and cell culture system was established
for both CCSK and CMN; the immunohistochemical, gene expression, and functional
analysis of the p53 tumor suppressor in cell cycle control signal transduction was performed;
and Northern blot analysis of genes relevant to normal nephrogenesis was examined.
The histologic, ultrastructural, and molecular features of CCSK and CMN nude
mouse xenografts, some of which have been passaged over several years, retained the
characteristics of the primary tumors. Similarly, cell cultures derived from either primary
tumors or mouse xenografts maintained cellular and molecular profiles consistent with
findings for primary tumors.
p53 mutation is a marker for poor prognosis in Wilms' tumors. p53 immunoreactivity
was absent from a large panel of CCSK and CMN primary tumor specimens examined.
However, immunohistochemical analysis of CCSK and CMN tumor celllines surprisingly
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revealed p53 immunoreactivity in both CMN cell lines but in none of the CCSK cells
examined suggesting that p53 was mutated in the benign CMN tumors. Functional analysis
ofp53 in the same CCSK and CMN cell culture system using a DNA damaging agent cisdiamminedicholroplatinum (100 J-lM) demonstrated the presence of functional p53 as
determined by the upregulation of p21

Waj-IICip-1

mRNA and G 1 cell cycle arrest over an

eight hour period.
The histogeneses ofCCSK and CMN is not known. CCSK and CMN primary tumor
tissue was examined for mRNA expression of the genes WT-l, PAX-2, Pax-8, and tenascinC, all genes relevant to normal kidney development. CCSK and CMN were generally
negative for WT-I, PAX-2, and Pax-8 expression. CMN, but not CCSK tumor specimens,
were positive for tenascin-C mRNA. To evaluate further the histogenesis of these tumors,
cultured CCSK and CMN cells were treated with the differentiation agent all-trans retinoic
acid (1 JlM) over three days. Induction of several genes were noted during this period such
as PAX-2 and tenascin. The expression of IGF-2, IGF-BP2, and p21 waj-J1cip -1 were also
modulated by this treatment. There were no light microscopically evident changes in cellular
morphology in either CCSK or CMN cells. However, transmission and scanning electron
microscopic analysis of the cells demonstrated closer cellular juxtaposition and flattening.
These studies indicate that the in vivo and in vitro model system for CCSK and CMN
will be useful in further investigating the molecular pathological relationships and
tumorigenic mechanisms in pediatric renal tumors. The apparant absence ofp53 functional
impairment in CCSK distinguishes this aggressive tumor type from anaplastic Wilms'
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tumors which often bear mutation of p53 and suggests an alternative genetic explantion for
the poor prognosis ofCCSK. Further, a deeper understanding of the gene expression profile
of pediatric renal tumors and renal development will be useful in the diagnosis and treatment
ofCCSK, CMN, and Wilms' tumor. Both the CCSK and CMN xenografts and cell lines also
have potential utility in understanding the pathobiology of the developing fetal kidney as
well as other pathologies affecting both children and adults.

Chapter 1
Introduction

I. General Introduction

Pediatric renal tumors represent the sixth most common childhood malignancy
following leukemias, brain tumors, neuroblastic tumors, and soft tissue sarcomas
(Parham,1996). Wilms' tumor, or nephroblastoma, is by far the most common renal tumor
of childhood, representing 85% of all reported cases (Murphy et al., 1994). Other renal
tumors with distinct histological and prognostic features also affect the young child. These
tumors have been classified based on these distinguishing features by the National Wilms'
Tumor Study (NWTS) group.They include the benign, congenital mesoblastic nephroma,
(CMN) comprising 5% of all childhood renal tumors, the potentially metastatic clear cell
sarcoma of the kidney (CCSK) comprising an additional 5% of cases, and the malignant
rhabdoid tumor of the kidney (RTK) which comprises 2% of all renal tumors of childhood
and usually metastasizes widely leading to patient death (Murphy et al., 1994).The
histological differences between the childhood renal tumors are noted in Figure 1. Both
CMN and CCSK and their relationships with Wilms' tumor will be the subject of the present
study_
Wilms' tumor has been extensively characterized at the morphological,
immunohistochemical, cytogenetic, and molecular levels (Grundy et al., 1995). In contrast,
both CMN and CCSK have not been evaluated thoroughly except for a few reports
describing the light and electron microscopic distinction of these tumors from Wilms' tumor.
In addition, there are very few studies which have evaluated the molecular pathology of these
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two neoplasms. Therefore, questions as to the relationship between these two tumors and
their possible relationship with Wilms' tumor remain unknown. One report has suggested
that CMN represents the benign counterpart of the more aggressive CCSK (Yun, 1993). This
theory is based primarily upon the similar stromal histology of these two neoplasms which
differs from the triphasic histology (Le., consisting of stroma, immature tubuli, and
blastema) of Wilms' tumor. Although light and electron microscopic studies can provide
valuable clues to the histogenetic origins of these two tumors, additional cellular and
molecular based investigations will need to be applied to address this question thoroughly.
The present study is an effort to address the cellular and molecular biology ofCMN
and CCSK, detennine if and how these tumor types are related to Wilms' tumor, and
investigate their histogenetic origins. To address the pathology of CMN and CCSK, the
following hypotheses are derived from the current literature and preliminary findings:
1. Both nude mouse xenografts (heterotransplants) and cultured cells derived from
CMN and CCSK tumor tissue will maintain the characteristics of their respective
primary tissue and provide models for the future study of these neoplasms.
2. Both CMN and CCSK cells exhibit different molecular biological aberrations
which are distinct from those in Wilms' tumor; and,
3. CMN, CCSK, and Wilms' tumor have distinct histogenetic origins within the
human developing kidney.
II. Historical Background
1. Genetic Etiology of Wilms' Tumor: Initiating Factors

Wilms' tumorigenesis is thought to occur during the fonnation of the metanephric
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kidney because the histology of this tumor closely parallels the appearance of the structures
visible during the course ofnonnal development (Figure 2 ). Specifically, these structures
include closely opposed blastematous tissue characterized by basophilia and high nuclear to
cytoplasmic ratio, the formation of immature renal tubular elements, and the presence of cells
of stromal lineage (e.g., fibroblastic cells, muscle cells, etc.) (Parham, 1996). In addition,
nephrogenic rests represent foci of undifferentiated renal tissue that are found in 0.01 % of
all infant autopsies (Murphy et al., 1994). Nephrogenic rests are also found in 0.40% of
unilateral Wilms' tumor cases and 1.2% of synchronous bilateral Wilms' tumors and are
thought to be tumor precursor lesions (Park et al., 1993). Although Wilms' tumor is widely
accepted as an aberrancy of normal renal morphogenesis, the genetic etiology of this
neoplasm is very complex.
The genetic basis of Wilms' tumor was initially thought to follow the pattern of
another embryonal neoplasm, retinoblastoma. Both retinoblastoma and Wilms' tumor may
occur either sporadically or be familial in nature. This feature led Knudson to describe his
classical "two-hit hypothesis" years before the actual identification of either the Rb or WT-J
tumor suppressor genes. His hypothesis stated that those children with bilateral tumors
inherited one defective allele (i.e., mutated, deleted, etc.) and acquired one additional somatic
mutation before the development of a tumor. In contrast, mutations in both alleles occurred
somatically in children with sporadic, unilateral cases of retinoblastoma and nephroblastoma
(Knudson et al., 1972).
The genetic etiology of Wilms' tumorigenesis first became evident upon the

5

karyotypic observation that patients with WAGR syndrome (Le., a genetic syndrome
characterized by Wilms' tumor, aniridia, genitourinary

malformations, and

mental

retardation) harbored large germline deletions on one chromosome 11 p 13 allele (Grundy et
al., 1979). Patients with the WAGR syndrome were later reported to harbor point mutations

in the other WT-l allele (Baird et al., 1992). Evidence for a putative Wilms' tumor gene
mounted later with the observation that some sporadic cases of Wilms' tumors, those not
associated with the WAGR syndrome, demonstrated loss of heterozygosity (LOR) at
chromosome 11p13 (Fearon et al., 1984; Koufos et al., 1984). The localization of a small
11 p 13 deletion led to the identification of a gene encoding a (Cys )2-(His)2 zinc finger
transcription factor at this locus which was designated WT-J (Call et al., 1990). Later work
showed that alternative RNA splicing at two sites, one of which created a three amino acid
(KTS) addition between the third and the fourth zinc fingers and the other which deletes exon

5, produced four discrete WT-J transcripts (Haber et al.,1991). The role(s) of the four
transcripts remain(s) unclear.
Additional evidence later came with the observation that patients having DenysDrash syndrome, a genetic disease characterized by genitourinary malfonnations and a
predilection for Wilms' tumor, harbored dominant point mutations that affect the WT -1 zinc
fingers ( Pelletier et al., 1991). WT-J gennline mutations have also been identified in DenysDrash patients and in several cases of bilateral Wilms' tumor (Pelletier et al., 1991; Ruff et

al., 1991).
WT-J mutations were later described in nephrogenic rests, foci of primitive renal
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cells that are found admixed with normal renal tissue in children with or without Wilms'
tumor and areas thought to represent precursor lesions of Wilms' tumor (Park et a/., 1993).
In this study, two separate cases of nephrogenic rests harbored a somatic mutation in WT-l
that was identical to the mutation in the primary Wilms' tumors. WT-J knockout mice studies
further demonstrated the involvement of WT-J in urogenital development as those mice
without functional WT-l failed to form a functioning metanephros due to the absence of
ureteric bud outgrowth. Defects in the mesothelium, heart, and lungs were also reported in
these same WT-J knockout mice indicating the importance of this gene in other organs, as
well (Kreidberg, et a/., 1993). Surprisingly, however, constitutional and tumor-specific WT1 mutations occur in only 10% of sporadic Wilms' tumor. In addition, many tumors
contained only one WT-J mutation, with the other allele being apparently normal (Haber et
aI., 1990). Because most Wilms' tumors overexpress

WT-J mRNA and lack any

demonstrable mutation, other, unexplored mechanisms which inactivate the function ofWT1 may exist.

Insulin-like growth factor II (IGF-2), a fetal mitogen, is reportedly overexpressed
in Wilms' tumor and several other childhood tumor types (Reeve et al., 1985). Further, the
use of a monoclonal antibody, aIR3, directed against the cognate receptor of IGF-2, the
insulin-like growth factor type I receptor (I GF -1 R) inhibited the growth of cultured Wilms'
tumor cells and the growth ofheterotransplanted Wilms' tumors in nude mice (Gansler et

al., 1989). In addition, the use of suramin, a polysulfated naphthyl urea compound which is
thought to interfere with IGF-2 binding with its cognate receptor, IGF-IR, inhibited the
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growth of Wilms' tumor both in vitro and in tumor xenografted mice (Stein, 1993; Vincent
et al., 1996a). This information suggests a role for an IGF -2 autocrine growth loop in Wilms'

tumor" cell growth.
The in vivo target genes of the WT-l transcription factor during nonnal renal
organogenesis remain largely unknown. However, putative target genes have been identified
predominantly through in vitro transactivation experiments. WT -1 appeared to bind
promoters with guanine-cytosine (GC)-rich DNA sequences such as the early growth
response (EGR)-l consensus site, and led to transcriptional repression (Rauscher et al.,
1990). One of the presumptive WT-l targets is the IGF-2 gene. The major IGF-2 promoter
was defined in transient transfection assays as a region spanning from nucleotides -295 to

+135, relative to the transcription start site. WT -1 bound to multiple sites within this region
and functioned as a potent transcriptional repressor of IGF-2 in vivo (Drummond et al.,
1992). WT-l also modulates the expression of the insulin-like growth factor one receptor
(IGF-l R), a receptor which mediates the cellular action of the mitogen IGF-2. In a series of

tumors examined, IGF-1R mRNA levels were inversely correlated with the expression of

WT-l. Further, in the same study, cotransfection of Chinese hamster ovary cells with rat and
human IGF-l R gene promoter constructs driving luciferase reporter genes and WT-l
expression vectors demonstrated that the WT-l gene product represses IGF-1R promoter
activity (Werner et ai., 1993). This evidence suggests a role for an IGF-2 autocrine growth
loop as a transforming mechanism in Wilms' tumor cells.
WT -1 modulation of cell growth is not limited to the insulin-like growth factors and
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their receptors. In transient transfection assays, WT -1 inhibited transcription of the plateletderived growth factor A-chain (PDGF-A) gene, a growth factor overexpressed in many
tumor types, by binding to a highly GC-rich region of the PDGF-A promoter as assessed by
gel mobility shift assays (Wang et al., 1992). WT-1 also repressed transfonning-growth factor
beta one (TGF-fJ) gene expression (Dey et aI., 1994). In other studies, WT -1 repressed the

Bcl-2, c-myc, and epidermal growth factor receptor promoters suggesting a role for WT -1 in
the complex control of programmed cell death, or apoptosis (Hewitt et al., 1995; Englert et

al., 1995).
The WT -1 gene product is reported to form a physical complex with another tumor
suppressor protein, p53. This association depends upon the structural integrity of both
proteins and has implications for both tumor suppressors' function. In the absence of
functional p53 protein, WTl appeared to attain potent transcriptional activation properties.
In addition, WTl synergized with p53 by enhancing its trans activating properties in one
report (Maheswaran et al., 1993). A later study found that the WT -1 gene product stabilized
the p53 protein and inhibited p53 mediated apoptosis without affecting G 1 cell cycle arrest
(Maheswaran et al., 1995). More recently, WT-l has been shown to induce the expression
of the cyclin-dependent kinase inhibitor p21 Waj-lICip-l preceding apoptosis, apparently in a p53independent manner suggesting a role for p21 in a WT -1 dependent programmed cell death
pathway (Englert et al' 1997). Table 1A summarizes the action ofWT-Ion its various target
J

genes.
Other potential Wilms' tumor loci have been suggested and include sites located on
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chromosomes I1p15, 16q, and a familial locus at chromosome 17q (Pritchard-Jones et al.,
1997). The 11 pIS locus, the site of the putative WT -2 gene, was initially identified as a
region of specific allele loss in Wilms' tumors and later found to contain the genes
responsible for Beckwith-Wiedemann syndrome (BWS), an autosomal dominant genetic
disease characterized by fetal overgrowth ( Moulton et al., 1996). Children with BWS have
a much greater chance of developing malignant tumors including hepatoblastomas and
nephroblastomas relative to the general population. Approximately 10% of BWS children
developed a childhood neoplasm in one report (Junien, 1992).
Several chromosome Ilp15.5 imprinted genes have been implicated in the
development of both Wilms' tumor and BWS. One of the genes residing at this locus was
the paternally expressed autocrine growth factor IGF-2 gene, a gene that showed
pathological biallelic expression in some tissues due to loss of imprinting (Weksberg et al.,

1993). IGF-2 is overexpressed at both the mRNA and protein levels in most cases of Wilms'
tumor examined (Reeve et al., 1985; Scott et al., 1985), H19 is a maternally expressed,
untranslated RNA that may serve as a tumor suppressor gene also located at chromosome
Ilpl5. In one study, the inactivation of H19 correlated with the reciprocal activation of the
IGF-2 maternal allele in Wilms' tumor and contributed to tumorigenesis either by its cis

effect on IGF2 expression or via elimination of a trans growth-inhibiting effect of H19
mRNA, or via both mechanisms (Hao et al., 1993). The actual role of H19 in the modulation
of IGF2 expression, however, is unclear.
More recently, attention has focused on another 11 pI5 gene, the cyelin-dependent
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kinase inhibitor p57KlP2 as a candidate for the WT-2 tumor suppressor. p5 7KlP2 was reported
as a structurally distinct member of the cyelin-dependent kinase inhibitor family which also

includesp21wa/-llcip-l and mapped to chromosome Ilp15.5 in the vicinity of reported BWS
breakpoints (Matsuoka et al., 1995; Hoovers et al.,1995). Analysis of the entire coding
sequence and intron-exon boundaries of p57K1P2 in 40 unrelated cases ofBWS revealed that
only two patients (5%) harbored mutations, both of which were frameshift mutations in exon
two (Lee et al., 1997). Another report which analyzed nine patients with BWS demonstrated
that 22% of the cases harbored p57K1P2 mutations (Hatada et ai., 1996). Whereas only a few
cases ofBWS reportedly harbor p57K1P2 mutations, an analysis of twelve primary Wilms'
tumors revealed no mutations in this cyetin-dependent kinase inhibitor gene (O'Keefe et

al., 1997). Others have suggested that non-mutation cases ofBWS and Wilms' tumor might
still be caused by down-regulation of p57KIP2 expression via uni-parental paternal disomy

(Henry et al., 1991).
A recent study of one Wilms' tumor pedigree by linkage analysis has suggested
another potential predisposition gene located at chromosome arm 17q12-q21 (Rahman et

al., 1996). This study conceded, however, that chromosome 17 can be excluded as the site
of a predisposing gene in several smaller pedigrees which were examined.
The initiating genetic factors leading to Wilms' tumor are undoubtedly very
heterogeneous. WT-J, once thought to be the sale initiating factor for Wilms' tumorigenesis
is deleted or mutated in only 10% of cases. Likewise, genes located at chromosome 11 p 15
including IGF2, H19, and p57KlP2 still have unclear roles in the development of Wilms'

11
tumor. The variability and large number of genetic lesions found in Wilms' tumors to date
testifies to the fact that the tumorigenic factors responsible for the development of this
childhood neoplasm are very complex and poorly understood.

2. p53 Signal Transduction: Cell Cycle Control and Apoptosis
The p53 tumor suppressor gene is located on the short arm of chromosome 17 and
encodes a 53 kiloDalton (kD) nuclear phosphoprotein that is a negative regulator of cellular
proliferation (Levine et al., 1991). p53 mutations were relatively common in a large number
of adult-onset tumor types including breast, lung, and colon carcinomas, but relatively rare
in childhood malignancies (Nigro et al., 1989). Wild-type p53 was present in extremely small
quantities in most cell types analyzed due to rapid turnover mediated by the ubiquitindependent degradation pathway (Kastan, 1991). In contrast, tumor cells with a mutant p53
molecule demonstrated over-expression of p53 protein using either Western blotting or
immunohistochemistry due to increased stability of the protein (Esrig et al., 1993).
Therefore, p53 protein overexpression is routinely used as a marker for a mutated p53 gene.
p53 is a mediator of diverse cellular processes including cell growth arrest, repair
of DNA damage, and induction of programmed cellular death or apoptosis. p53 protein was
induced following exposure to DNA damaging chemotherapeutic agents, ionizing radiation,
and ultraviolet irradiation (Ko et al., 1996). Several studies have suggested that p53 'senses'

DNA damage by signalling through an upstream initiating factor ATM, or mutated in ataxia
telangiectasia protein, a protein that is homologous to members of the DNA-protein kinase
gene family (Hawley et al., 1996). p53 mediates cell cycle arrest and programmed cell death
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via several downstream effector genes. A substantial number of genes containing p53
response elements within their promoters have been identified (Table IB).
The p21 waf-llcip-l is a cyclin-dependent kinase inhibitor which is transactivated by the
wild-type p53 protein to effect cell cycle arrest. In seminal reports, p21 prevented cell cycle
progression by binding to cyclin-cyclin dependent kinase complexes and preventing
phosphorylation 0 f proteins further downstream including the retinoblastoma protein Rb (EIDiery et ai., 1993; Xiong et ai., 1993). p21 also blocked the activity of the proliferating cell
nuclear antigen which is important for S-phase cell cycle entry (Waga et ai., 1994).
Additional evidence demonstrated that DNA damage created by gamma irradiation induces
p53-dependent G 1 cell cycle arrest that is mediated, at least in part, by the induction ofp21
mRNA (EI-Diery et ai., 1994). Induction ofp21 is often used as a measure ofpS3 function.

In a comprehensive report on over 120 cell lines treated with radiation and different
chemotherapeutic agents,p21 induction at both the mRNA and protein levels were used as
determinants of the functional integrity of the p53 tumor suppressor gene (O'Connor et ai.,
1997).

p21 is also upregulated by p53-independent mechanisms after exposure to

differentiating agents such as all-trans retinoic acid, butyrate, or dimethylsulfoxide in HL-60
cells (Steinman et ai., 1994).
A variety of other p53 mediators have been described. Other genes which contain p53
response elements include Bax and MDM-2. In a seminal report, Bax was induced in
response to p53 expression and encoded a pro-apoptotic protein with homology to the
cellular survival factor Bcl-2 (Miyashita et a/., 1995). The induction of Bax in response to
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ionizing radiation appeared to correlate with the mutational status of p53 in human cells.

Cells with wild-type p53 actively induced Bax expression whereas mutant p53 protein failed
to do so (Zhan et al., 1994). Initiation of the apoptotic cascade appears to depend upon the
ratios ofBax to Bcl-2 protein. Bax-Bax homodimers favored apoptosis, whereas Bax-Bcl-2
heterodimers were inhibitors of programmed cell death (Oltvai et al., 1993). Bax is,
therefore, a link between p53 and the initiation of apoptosis in those cells that are subject to
stress signals, such as gamma irradiation or challenge with chemotherapeutic agents.
MDM-2 is a protein which complexes with p53 and inhibits its transcriptional
activation ability (Oliner et al., 1993). The MDM-2 gene itself was shown to be a
transcriptional target of p53 which is activated in response to cell damaging signals. The
latter is suggestive of an auto-regulatory feedback loop which exists between p53 and MDM2 (Wu et al., 1993; Burak et al., 1993). In addition, MDM-2 overexpression is known to
inhibit p53-dependent G 1 cell cycle arrest in response to irradiation. A peak in MDM-2
protein occurs later than p21 protein offering evidence that MDM -2 can down-regulate p53
after the cell has repaired DNA damage (Chen et al., 1994). Crystallography experiments
have recently identified the exact location of the p53-MDM-2 interaction. An alpha-helical
section of the p53 transactivational domain interacts with a deep hydrophobic cleft of the
MDM-2 protein leading to the suppression of p53-mediated transactivation (Kussie et

ai., 1996). More recently, MDM-2 has been demonstrated to promote the rapid degradation
ofp53 protein counteracting its accumulation following genotoxic stress (Haupt et al., 1997).

14
The role of the MDM-2 proto-oncogene in the development of human tumors is well
studied. The MDM-2 gene is amplified in approximately 30-40% of all human sarcomas
analyzed but rarely amplified in a large number of pediatric solid tumors examined (Oliner

et al., 1992; Waber et ai., 1993). MDM-2 was over-expressed, however, in a number of
pediatric cases of rhabdomyosarocma (Kaleti et ai., 1996)
Others p53 target genes include the DNA repair gene GADD45, cyclin-G, the insulinlike growth factor binding protein-3, an anti-angiogenic molecule, Thrombospondin-l,

cyclin-D, and several others (Ko et ai., 1996).

3. p53 and Anaplastic Progression in Wilms' Tumor
The vast majority of classical Wilms' tumors are cured with the successful
combination of chemotherapy, radiation therapy, and surgery. A small minority of Wilms'
tumors (approximately 5.0%) are believed to progress to a more malignant phenotype
characterized by the development of morphological anaplasia (Parham, 1996). Anaplastic
cells are defined as those having extremely large nuclei with multipolar mitotic figures,
hyperchromasia, and great variability in cell size. Anaplasia is associated with a high degree
of chemotherapeutic resistance, but not necessarily increased tumor aggressiveness. Classical
Wilms' tumors that have been successfully propagated in nude mice demonstrated no
evidence of progression to morphological anaplasia after numerous passages. Therefore,
direct evidence of anaplastic conversion has not been substantiated. One report, however,
indicated that a metachronous anaplastic tumor developed within the tumor bed of a treated
classical Wilms' tumor patient, thereby suggesting that classical tumors may progress into
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its more malignant anaplastic counterpart (Oesterling eta!., 1987). Therefore, this study links
these tumor histologies together in a continuum of time. More recent molecular biological
assessment of Wilms' tumors has upheld the putative link between classical and anaplastic
Wilms' tumors. Figure 3 represents a genetic model of Wilms , tumorigenesis and anaplastic
progresSIon.
Several studies have examined the mutational status of the p53 tumor suppressor in
Wilms' tumor. In one study,p53 was mutated in two out of21 cases examined, or 9.5% of
all cases. One of the cases harbored morphological features of focal anaplasia (Malkin et al.,
1994). In another more comprehensive study of 140 cases, p53 mutations were documented

in eight of eleven anaplastic Wilms' tumors; the remaining 129 cases that did not exhibit
anaplasia did not harbor p53 mutations. The latter suggested that p53 is a marker of
anaplasia and is a gene, when defective, that is responsible for the poor outcome in patients
with morphological features of anaplasia (Bardeesy et al., 1994). In another study of three
anaplastic Wilms' tumors,p53 mutations were documented in two of the three cases. One
mutation created a truncated protein that was undetectable using immunohistochemical
methods suggesting that immunochemistry should not be used alone in assessing the
mutational status ofp53 in these tumors. The other mutation was a point mutation at codon
273, a "hotspot" mutation, which rendered the protein product more stable and thus
detectable using immunochemistry. The third case affected an older patient but no mutation
was detected in this tumor even though immunohistochemical analysis using fixed primary
tumor tissue suggested the presence of p53 mutations

(EI Bahtimi et aI., 1996).
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Additionally, Lahoti demonstrated a tendency for p53 mutations to occur in the majority of
a series of invasive and metastatic Wilms' tumors using immunohistochemistry. p53
immunoreactivity was not, however, limited to either anaplastic or metastatic cases of
Wilms' tumor. Lahoti suggested that the presence of other p53 binding proteins were
responsible for the latter immunophenotype in the classical Wilms' tumors (Lahoti et al.,
1996). However, amplification or overexpression of the p53 binding protein MDM-2, which
can bind to and stabilize the p53 protein creating an immunophenotype similar to a mutated
fonn of the protein, was not an alternative means for p53 inactivation in a large series of

Wilms' tumors examined (Bardeesy et al., 1994).
Anaplastic Wilms' tumors are potentially aggressive tumors that are more resistant
to the conventional Wilms' tumor chemotherapeutic treatment regimen of vincristine,
vinblastine, and actinomycin D. A link between p53 mutation and the development of a drug
resistant phenotype has recently been described. The anaplastic Wilms' tumor cell line W4
contained a thymine deletion at codon 212 which is responsible for a frame shift leading to
a TGA stop signal at codon 246. The resulting p53 protein was truncated and non-functional
(EI Bahtimi et a/., 1996). The W4 anaplastic Wilms' tumor cell line also overexpressed the
MDR-l gene in a separate study (Re et al., 1997). MDR-J was not ampified in case W4 as
assessed by Southern blotting, but was overexpressed at the mRNA level. P-glycoprotein
function in the W 4 cell line was inhibited by the calcium channel blocker verapamil in an in

vitro

daunomycin nuclear fluorescence accumulation assay. Mutation of p53 and

overexpression of MDR-J in this anaplastic Wilms' tumor was found to be consistent with

17
the clinical outcome of patient W4, as the patient died of multipile metastatic lesions.

The MDR-J and p53 genes are functionally linked. In vitro transactivation studies
containing a reporter gene under the control of the MDR-J promoter indicated that wild-type

p53 acts as a transcriptional repressor of the MDR-J gene and inactivating mutations ofpS3
released this gene from repression (Chin et aI., 1992; Nguyen et al., 1994). Evidence from
studies of the W4 cell line supported these latter findings and suggested that p53 and MDR-1
are linked to both anaplastic progression and the development of a drug resistant phenotype
in Wilms' tumors.
Although p53 is mutated in a high percentage of the anaplastic Wilms' tumor cases,
other chromosomal linkage studies have suggested the presence of other genes which
predispose patients to a poor outcome. LOR at chromosome 16q was a non-random
chromosomal abnormality in a series of Wilms' tumors. Significant loss of areas on
chromosome 16q were present in nine of 45 informative cases ( Maw et al., 1992). Another
report indicated that patients with deletions on chromosome 16q had relapse rates 3.3 times
and mortality rates 12 times that of those patients that do not demonstrate LOR at
chromosome 16q (Grundy et aI., 1994). The latter study also reported that chromosome 1p

LOH in Wilms' tumor was a non-random event and linked to mortality rates three times
higher than rates for patients without LOH.
4. Genetic Basis of Kidney Development with Implications for Pediatric Renal Tumor
Histogenesis
The development of the kidney begins around embryonic day 19 and progresses
through the pronephric, mesonephric, and metanephric stages before reaching maturity. The
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definitive, functioning kidney of the postnatal period and beyond is the metanephros which
fonns as a result of a mesenchymal-epithelial transition. Around embryonic day 28, the
metanephric kidney is induced in the sacral intermediate mesoderm (nephrotomes) of the
trilaminar embryo by the ureteric buds, outgrowths of the distal portions of the Wolffian duct
(mesonephric ducts). The ureteric buds subsequently penetrate beds of mesenchymal tissue
termed the metanephric blastema spurring the mesenchyme to condense around the apical
aspects of the ureteric bud. The ureteric bud and the metanephric blastema exert reciprocal
inductive effects during this period causing continuation of mesenchymal condensation and
further bifurcation of the ureteric buds. Later in development, remnants of the ureteric bud
will constitute the collecting duct system whereas the condensed mesenchymal tissue
continues to differentiate through several distinct stages including the comma-shaped and
s-shaped bodies to eventually form the non-vascular elements of the glomerulus, the
proximal and distal convoluted tubules, and the loops of Henle ( Larsen, 1998). Recent
studies have begun to elucidate the cellular and molecular mechanisms underlying the
normal nephrogenesis and will undoubtedly offer new information which may be used to
interpret renal abnormalities including the development of pediatric renal neoplasia. Figure
4 presents a diagramatic representation of normal nephrogenesis.
The WT-J gene, first described in 1990, was localized to an area of chromosome 11
that was often deleted in Wilms' tumor (Call et a/' 1990). Besides its mutation or deletion
J

in Wilms' tumors, WT-J plays a pivotal role in the development of the mammalian urogenital
system. In a study of homozygous mutant WT-J mice, the ureteric buds failed to form
properly leading to degradation of the metanephric mesenchyme and renal agenesis.
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(Kreidberg et al., 1993). In the mouse fetal kidney, WT-l gene expression was relatively low
in the uninduced metanephric mesenchyme. Coincident with ureteric bud induction, the
mesenchyme expressed increased levels of WT-l indicating the importance of this gene in
this developmental stage (Pritchard-lones et al., 1990; Armstrong et ai., 1992). WT-l
expression remained high during the formation of the early nephron precursors, but as the
kidney matured, expression was limited to the glomerular podocytes (Ryan, 1995).
The Pax genes are other important mediators of the developmental regulation of
the kidney (Gruss et ai., 1992). The Pax gene family encodes evolutionary conserved
transcription factors which share a common motif, the paired box, which acts as a DNAbinding domain. Some of the first experiments which addressed the function of Pax-2 in
kidney development used gene knockout. Pax-2 knockout mice, specifically Pax2-/ mice,
w

failed to develop both kidneys and genitourinary tracts (Torres et aI., 1995). In addition,
antisense Pax-2 oligonucleotides used in kidney organ culture experiments demonstrated
mesenchymal condensation failure and absence of epithelial differentiation (Rothenpieler et

al., 1993).
Additional studies ofPax-2 function have been addressed in gene expression studies
of the fetal kidney and Wilms' tumors. In the metanephric mesenchyme, Pax-2 was
expressed in the early condensates and comma-shaped bodies, but expression declined in the
S-shaped bodies and was not expressed in mature nephron structures (Dressler et al., 1990).
Using in situ hybridization experiments, Pax-2 has also been localized in condensed blastema
cells of Wilms' tumors (Eccles et ai., 1995). Another report has also indicated that Pax-2 is
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abundantly expressed in a series of Wilms' tumors examined (Dressler et al., 1992).
Both WT-l and Pax-2 appear to be involved in a reciprocal modulation pathway.
Expression of Pax-2 is repressed in the presence of increasing amounts of a WT-J expression
vector as assessed by chloramphenicol-acetyl transferase reporter gene assays (Ryan et al.,
1995). More recently, another report using deletion mutagenesis experiments indicated that
Pax-2 positively modulated the expression of WT-J by binding to a sequence between 33 and
71 base pairs upstream of the WT-J start site (Dehbi, et al., 1996b).
Additional members of the Pax gene family implicated in early kidney development
include Pax-8. Somewhat different from Pax-2, Pax-8 was expressed in condensed
mesenchyme, comma-shaped bodies, S-shaped bodies, and immature tubular structures as
assessed by in situ hybridization studies. Pax-8 is also expressed in the developing thyroid
gland and in Wilms' tumors (Poleev et al., 1992). A later study indicated that Pax-8
expression was localized, in particular, to the condensed blastema cells of Wilms' tumors
(Eccles et al., 1995). Additionally, in transient transfection and gel-shift assays, Pax-8 was
demonstrated to transacti vate WT-J by binding to a 38 base pair conserved motif wi thin both
mouse and human promoters, similar to that which was described for Pax-2 (Dehbi et a/.,
1996a). Members of the myc family of transcription factors are expressed at different stages
of the kidney in a pattern similar to that of the Pax genes. In particular, N-Myc is highly
expressed in the condensing mesenchymal tissue during normal nephrogenesis (Mugrauer,
et al., 1991).

In addition to the large number of transcription factors involved in kidney
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morphogenesis, a variety of cellular adhesion molecules and extracellular matrix proteins
play a role in the proper development of the nephron. One of these extracellular matrix
proteins with relevance to understanding the histogenesis ofCMN and CCSK is tenascin-C.
Tenascin-C, also termed cytotactin, is a large hexameric glycoprotein that exhibits siterestricted expression patterns during the development of several organs and retains
expression in selected adult organs including the kidney. In addition to the nonnal expression
pattern of tenascin in the adult, it may be re-expressed in a number of pathologic conditions
such as sites of inflammation, wound repair, and some tumors (Crossin, 1996). The actual
function of tenascin is not clearly understood, as tenascin knockout mice

have not

demonstrated apparent pathologies (Saga et al., 1992).
In the developing kidney, the expression pattern of tenascin is restricted. In one study,
tenascin was not expressed by uninduced renal mesenchymal tissue, but was detectable in
the extracellular matrix of mesenchymal cells which surrounded the developing epithelial
cells. Additionally, tenascin seemed to be restricted only to those cells which gave rise to the
stroma (Aufderheide et al., 1987). The latter observations are consistent with the importance
of this molecule in mesenchymal to epithelial transitions which occur during the
developmental process. As nephrogenesis ceases, tenascin disappeared from the renal cortex
and was only expressed in the interstitial cells of the deep medulla (Aufderheide et al., 1987).
In another study, tenascin immunoreactivity was not limited to the renal medullary
interstitium, but was also found in the glomerulus, presumably secreted by the glomerular
mesangial cells. In the same report, glomerular tenascin immunoreactivity was found
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increased in the active phase of glomerulopathies and interstitial nephritides (Koukoulis et
al., 1991; Gould et al., 1992; Truong et at., 1996). Tenascin immunoreactivity is absent from

loose mesenchymal cells even though the latter cells are positive for fibronectin and neural
cell adhesion molecules (Ekblom et al., 1991). The expression of tenascin is distinct from

the cellular adhesion molecule expression pattern of kidney epithelial cells. These cells are
negative for tenascin while positive for E-cadherin and laminin-A (known markers of
epithelial cells in many tissue types). Tenascin, therefore, appears to be a marker for stromal
cells. The distribution of this protein may be useful in understanding the histogenesis of
pediatric renal tumors, particularly those which supposedly have stromal origins like CMN
and CCSK. A summary of the gene expression characteristics of the developing kidney and
pediatric renal tumors is summarized in Table II.
Intermediate filament proteins are also useful in understanding the derivation of
tumors and are employed most frequently by pathologists attempting to define the origin of
a tumor. For example, desmin and smooth muscle actin proteins are markers for smooth
muscle cells, while vimentin is a marker for cells of mesenchymal origin. The latter
intermediate filament proteins are useful in the diagnosis of connective tissue tumors, or
tf

sarcomas. In contrast, cytokeratins are markers for epithelilal cells and are often useful in the
diagnosis of carcinomas (Junquiera et al., 1992)

5. All-trans Retinoic Acid (atRA) Induced Differentiation of Tumor Cells
Retinoic acid is a well-known morphogen (Maden, 1985). As such, it has been used
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as a chemopreventive agent and a therapeutic agent in some types of leukemia. Retinoic acid
molecules along with their respective metabolites are analogs of Vitamin A, or retinol, an
agent with many cellular functions. Of particular importance in the analysis of tumor
histogenesis are the all-trans (atRA) and 9-cis retinoic acid molecules. The latter agents
effect their molecular and cellular modulations within the cell by binding to different types
of nuclear receptors termed retinoic acid receptor (RAR) and the retinoid-X receptor (RXR).
Both the RAR and RXR are heterocomplexes containing u,

f3 and y subunits. Transcription

of a number of target genes are influenced by binding of either a retinoid-RAR or retinoidRXR receptor complexes to retinoid acid response elements (RAREs) within their promoters.

Two tumor cell types, neuroblastoma and the promyelocytic leukemia cells HL-60,
are particularly amenable to atRA induced differentiation and have constituted the subject
of many studies regarding the mechanisms for this process. For example, atRA induced
growth arrest and neurite formation, structures which resembled axons and dendrites, in
many neuroblastoma cell lines in conjunction with downregulation of N-myc gene expression
(Wada et ai., 1992). Decreased expression of the c-myb oncogene also occurred upon atRA

induced differentiation in neuroblastoma cells (Thiele et ai., 1988). The levels of p53 mRNA
and protein declined in atRA stimulated LAN-5 human neuroblastoma cells consistent with
the notion that p53 is no longer needed in non-dividing cells (Davidoff et aI., 1992).Upon
stimulation with atRA, HL-60 promyelocytic leukemia cells were induced to differentiate
into cells of the granulocytic lineage (Olsson et ai., 1982).
More recently, atRA has been investigated in Wilms' tumor for its ability to initiate
differentiation in a blastemal predominant cell line (Vincent et ai., 1996b). AtRA arrested
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the proliferation of Wilms' tumor cells as assessed by tritiated thymidine incorporation
experiments. Arrest of cellular proliferation was associated with downregulation of N-myc.
However, light microscopic and ultrastructural analysis of these Wilms' tumor cells did not
exhibit any morphological signs of epithelial differentiation as assessed by the development
of cell polarity ~ microvilli, or junctional complexes.

5. Congenital Mesoblastic Nephroma: Molecular Biology and Histogenesis

CMN is the most common renal neoplasm of infants and was first distinguished from
the more common Wilms' Tumor by Bolande in 1967 (Bolande et a/., 1967). CMN
comprised approximately five percent of all pediatric renal tumors in one report with over
60 percent being diagnosed before three months of age (Murphy et al., 1994). The majority
of CMNs are benign, with surgery alone proving to be curative. Exceptions to this rule
include the clinical behavior of cellular (or atypical) CMN which had the ability to recur and
metastasize following incomplete resection of tumor at surgery (Beckwith et a/., 1986).
Histologically, the tumor is composed of interlacing fascicles of spindle-shaped fibroblasts
and myofibroblasts with round nuclei in its classical form (Pettinato et a/., 1989). Atypical
mesoblastic nephroma, also known as the cellular CMN, is a potentially aggressive variant

ofCMN with dense cellularity, many mitotic figures, necrosis, and hemorrhage (Joshi et a/.,
1986).
The histogenetic origin of CMN remains controversial. Nevertheless, it has been
proposed that this tumor arises from secondary mesenchyme (i.e. mesenchyme no longer
capable of differentiating into epithelial cells of the nephron, but into cells which form the
renal interstitium) (Yoon-Jung et a/., 1994). CMNs are

generally positive for the
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intermediate filament proteins desmin and smooth muscle actin, both of which are markers
for skeletal and smooth muscle differentiation, respectively. CMN is not immunoreactive for
markers of epithelial cells such as the cytokeratins (Pettinato et al., 1989). One report
demonstrated immunoreactivity for the Thy-l antigen in both CMN and renal interstitium,
but not in CCSK or Wilms' Tumor (Hazen-Martin et al., 1993). Some reports suggested that
CCSK may arise from a progression of the more benign CMN due to similarities in
histological and ultrastructural appearance (Haas et al., 1984). Others have proposed that
CMNs and CCSKs are one tumor with the potential to differentiate anywhere along the
stromal lineage of embryonic development into CMN, atypical (cellular) CMN, or CCSK
(Yoon-lung et al., 1994). In other words, because all of these tumor types resemble different
stages of stromal cell differentiation during fetal kidney development, tumorigenic events

may develop at key points in this developmental process resulting in either the cellular or
classical CMN, or CCSK.
Cytogenetic studies of CMN are relatively uncommon. Several studies have shown
that CMNs are often trisomic or tetrasomic for chromosome 11 (Kaneko et al., 1991).
Another report using fluorescence in situ hybridization studies of CMN also indicated that
chromosome 11 trisomy or tetrasomy is a common, non-random finding in a number of
CMN cases (Schofield et al., 1993). This study also reported an association of extra copies
of chromosome 11 with the cellular or mixed variant of CMN. In another report, northern
analysis indicated that two cases of CMN overexpressed IGF-2, a gene localized to
chromosome 11 p 15 (Tomlison et al., 1992). Overexpression ofIGF -2 is consistent with the
extra copies of chromosome 11 in these tumors and may represent a tumorigenic mechanism
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inCMN.
Molecular evidence for the concept that CMNs derive from the stromal lineage of
renal stem cells is incomplete. One study reported a lack ofN-myc and WT-J mRNA in two
cases of CMN, contrasting with the presence of WT-J and N-myc mRNA in Wilms' tumors
(Tomlison et al., 1992). In addition, WT-J is not expressed in the stromal component of
triphasic, classical Wilms' tumors (Eccles et al., 1995). The latter observation is consistent
with the hypothesis that CMN, being stromal in nature, arises from the same renal stem cell
as the stromal cell present in Wilms' tumors.

6. Clear Cell Sarcoma of the Kidney: Molecular Biology and Histogenesis
CCSK is a rare renal tumor affecting young children primarily between the ages of
one and three years, having a characteristic histologic appearance composed of clear nuclei,
abundant extracellular matrix production, and a fine interweaving network of blood vessels.
The latter features distinguish CCSK from the more common Wilms' tumor which is usually
composed of blastema, immature tubuli, and stromal cells. Clinically, CCSK is separated
from Wilms' tumors due to a marked propensity to recur after initial treatment and
metastasize to bone (Murphy et al., 1994). CCSK was first reported as a separate entity by
Kidd in 1970 when he described the "sarcoma of the kidney"as having a higher incidence of
bone metastases compared to the relatively benign Wilms' tumor which generally did not
metastasize (Kidd, 1970). Due to the latter, Kidd emphasized the distinction of CCSK from
Wilms' tumor in the diagnostic process. Since the initial report in 1970, other reports have
followed describing this tumor. The term clear cell sarcoma of the kidney as a descriptive
term for this neoplasm was first suggested in a subsequent paper (Beckwith et al., 1978). In
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the same year, Marsden and Morgan described this same tumor type and termed the tumor
bone metastasizing renal tumor of childhood and undifferentiated sarcoma of the kidney,
respectively (Marsden et al., 1978; Morgan et al., 1978). All of these reports found that this
tumor was distinguishable from Wilms' tumor based on its distinct histology and predilection
for the development of metastatic bone lesions.
The treatment of children with CCSK has been dramatically improved with the
addition of actinomycin D to the chemotherapeutic and radiation regimen. CCSK patients
now routinely receive vincristine, actinomycin D, doxorubicin, and cyclophosphamide in
addition to radiation therapy. Actinomycin D increased the six-year relapse-free survival
from 25.0% to 63.5% with the overall survival rate now approaching 70%. However, this
report noted that CCSK had the ability to recur several years after the initial diagnosis,
therefore necessitating the need for close patient follow-up years after the initial diagnosis.
This same report has further noted that etoposide and ifosfamide have been used successfully
in the treatment of CCSK patients (Green et aI., 1994).
Previous studies of the immunohistochemical and electron microscopic features of
CCSK have further distinguished this tumor from Wilms' tumors. Ultrastructurally, CCSK
contained round to oval nuclei with little heterochromatin, small nucleoli, primitive cellular
junctions, sparse Golgi apparati and endoplasmic recticulum, and a lack of epithelial
differentiation (Haas et al., 1984). Ishii, however, noted that CCSK had a latent epithelial
nature

evidenced by the fact that CCSK grown in culture produced mucin, had an

eosinophilic cytoplasm, and contained intracellular canaliculi (Ishii et al., 1989). The latter
report further noted that some CCSKs, like Wilms' tumors with primitive epithelium, were
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immunoreactive for cytokeratins 8 and 19, markers of renal tubular epithelium. Other
immunohistochemical studies indicated that CCSKs were negative for epithelial membrane
antigen as well as for markers of smooth muscle, endothelial cells, neural tissue, and cells
of the immune system. CCSK cells were only positive for vimentin consistent with the
mesenchymal character of this tumor (Looi et ai., 1993).
The cytogenetic and molecular genetic characteristics of CCSK remain relatively
scanty. A few case reports do exist, however. Punnett reported the first cytogenetic study of
CCSK (Punnett et ai., 1989). This study demonstrated a consistent karyotype of

46,XY,t(10;17)(q22;p13) in all cells examined of an individual patient. The constitutional
karyotype of peripheral blood lymphocytes from the same patient was normal 46,XY,
however. Punnett further speculated that p53 may be involved in the tumorigenic events of

CCSK since this tumor suppressor is located at 17p 13, the region involved in the
chromosomal breakpoint. Another potential gene interrupted by this translocation was the
early growth response gene-2 (EGR-2) located at chromosome 10q22. Other reports
indicated extensive cytogenetic abnormalities in CCSK including a loss of the short arm of
chromosome 11 (Wang-Wuu et ai., 1990). Another report analyzed four cases ofCCSK and

found that the majority of cases were normal. However, one case in which the patient
eventually died was found to have a chromosomal 22 translocation t(2;22)(q21;q 11) (Kaneko

et al , 1991). Deletion of chromosome 22 in CCSK has also been reported (Douglass et aI.,
1990). Cytogenetic aberrations or LOH at chromosome 22q loci also occur in the RTK,
another renal tumor of childhood with a poor prognosis (Douglass et al., 1990; Schofield et

ai., 1996).This association may suggest a common origin for both CCSK and RTK.
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Molecular biologic characterization ofCCSK is limited. Yun used Northern analysis

and in situ hybridization and demonstrated that CCSK did not express WT -1 mRNA, a gene
with known involvement in the early development of the kidney, but was positive for IGF-2
mRNA (Yun, 1993). Based on these findings along with immunohistochemistry and electron
microscopy, Yun speculated that CCSK is derived from either loose metanephric
mesenchyme or from stromal cells at an early stage of differentiation. One study reported that
the WT-l gene contains no gross abnormalities (i.e. gene rearrangements) in five CCSKs
examined

by

Southern

blotting

(Kikuchi

et aI.,

1992).

More

recently,

an

immunohistochemical examination of several cases of CCSK demonstrated strong nuclear
immunoreactivity using monoclonal antibodies directed against p53, suggesting mutations
in these tumors types (Cheah et al., 1996). No molecular biological or functional
confirmation has been performed for these tumors.
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Figure 1. Hematoxylin and eosin stained sections of pediatric renal tumors. A, cellular

congenital mesoblastic nephroma; B, clear cell sarcoma of the kidney (m

= collagenous

extracellular matrix material; the arrow indicates the characteristic empty appearing nuclei
of this tumor); C, classical, triphasic Wilms' tumor (s = stromal tissue, b = blastema, and t
=

immature tubuli), and D, Malignant rhabdoid tumor of the kidney. All micrographs at

250X.
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Figure 2. Histological comparison of fetal kidney tissue and Wilms' tumor. A, fetal kidney

at approximately 10 weeks of development; B, Classical Triphasic Wilms' tumor. Three
histologic components are noted in each specimen ( white asterisks = blastema, large arrows
= immature tubuli, and small arrows = stromal tissue).
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Figure 3. Model for Wilms' tumorigenesis and progression indicating the proposed sequence

of WT-l and p53 mutations ( WT == Wilms' tumor; A WT == anaplastic Wilms' tumor).
Adapted from Re GG et al., Seminars in Diagnostic Pathology 11(2): 126-135, 1994.
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Figure 4. Normal development of the kidney. A, loose mesenchyme with the beginning of
mesenchymal condensation; B, condensation around ureteric bud; C, comma shaped stage
of development; D, S-shaped stage of development; E, early tubulogenesis; F,
glomerulogenesis with invasion by blood vessels. Adapted from Saxen L, Organogenesis of
the Kidney, 1987.

D:

Fig.

1._20~A

to F . Semi~schematic illustration of- the early development of tb·e
nephron from condensation to the S. .sbaped body (after Saxen 1984a).
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Table lA. WT-l Transcriptional Modulation of Target Genes with Proposed Biologic
Effects
WT-1 transcriptional
target

transcriptional
modulation of gene
expression

proposed biological
effects of gene
expression regulation

IGF-2

negative

decreased cell
proliferation

IGF-1R

negative

decreased cell
proliferation

PDGF-A

negative

decreased cell
proliferation

TGF-fJ

negative

decreased cell
growth

Bcl-2

negative

apoptosis

c-myc

negative

apoptosis

p21

positive

apoptosis

waf-I

Table lB. p53 Transcriptional Modification of Target Genes with Proposed Biologic
Effects
p53 transcriptional target

transcriptional
modulation of gene
expression

biological effects of
gene expression
modulation

p21

positive

cell cycle
apoptosis

Bax

positive

apoptosis

MDM-2

positive

negative regulator
ofp53

GADD-45

positive

DNA repair

IGF-BP3

positive

decreased cell
proliferation

thrombospondin-l

positive

angIogenesIs
inhibited

waf-l

.

arrest~

.
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Table 2. Summary of Gene Expression Analysis of Developing Kidney Tissue and
Pediatric Renal Tumors

Condition

WT-l

Pax-2

Pax-8

Tenascin -C

mRNA

mRNA

mRNA

mRNA

loose
(uninduced)
renal
mesenchyme

negative

negative

negative

negative

condensed
(induced) renal
mesenchyme

positive

positive

positive

negative
stromal
containing
Wilms' tumors
are positive

Wilms' tumors

positive

positive

positive

CCSK

negative

some
positive

negative

some
positive

CMN

some
positive

some
positive

negative

positive

Chapter 2
Materials and Methods

I. Tumor Specimens
Two cases of CCSK and two cases of cellular CMN were obtained from the Surgical
Pathology division at the Medical University of South Carolina (MUSC). These tumors were
designated CCSK-2 and CCSK-4. CMN from Muse are referred to as CMN-1 and CMN-2.
Both CMN-1 and CMN-2 are cellular (atypical) forms of the disease. One case ofCCSK was
obtained fresh from the Department of Pathology at Wake Forest University School of
Medicine (WFUSM) and was designated CCSK-BG 1. Two other cases of CCSK were
provided from Timothy Triche, M.D., Ph.D. of the Children's Hospital Los Angeles and
were designated CCSK-1 and CCSK-3.
Snap frozen tissues of two classical and three cellular CMN, five CCSK, and the
matching adjacent normal kidney for each of the latter tumor types were obtained through
application to the National Wilms' Tumor Study repository. CCSK cases are designated
CC209, CC236, CC462, CC50057, and CC50113. CMN cases are designated CMN357,
CMN458, CMN482, CMN50044, and CMN50524. CMN 357, CMN50524, and CMN50044
are all cellular forms of the disease designated by the prefix ce-. CMN458 and CMN482 are
classical forms of the disease designated by the prefix cl-.
II. Chemicals
Unless otherwise specified, routine chemicals for use in this study were obtained from either
Fisher Scientific (Atlanta, Georgia) or Sigma Chemical Company (St. Louis, Missouri).
Chemical reagents used for electron microscopic studies were purchased from Electron
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Microscopy Sciences (Fort Washington, Pennsylvania).

III. Nude Mouse Heterotransplantation
Primary CCSK and CMN tumors were removed surgically and maintained in either
saline or Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL,Grand Island, New
York) supplemented with penicillin-streptomycin and 15% fetal calf serum (Gibco BRL)
before injection into mice as previously described (Garvin et ai., 1988). Tumor specimens
were minced finely and injected subcutaneously using a 16-gauge needle into 6-10 week old
Balb/c nude mice (National Cancer Institute, Bethesda, Maryland). Mice bearing tumors of
the appropriate size (approximately 8-12 cm3) were sacrificed. Tumor nodules were excised
aseptically, minced finely, and again injected subcutaneously into additional nude mice.
Additionally~

excised nude mouse heterotransplant tissue was either snap frozen or used to

establish cell cultures. Heterotransplant histology was evaluated at each passage to compare
with the primary tumor specimen.

IV. Tumor and Heterotransplant Tissue Fixation, Processing, and Hematoxylin and
Eosin Staining
Following removal of the tumor or tumor heterotransplant, tissue was minced into
small pieces (approximately 1-2 cm3) and fixed for 8-10 hours at room temperature in either
10% neutral buffered formaldehyde (NBF) or Camoy' s solution (60% absolute ethanol, 30%
chloroform, 10% glacial acetic acid). Following fixation, tissues were stored in either 70%
(NBF fixed tissue) or 100% (Camoy's fixed tissue) ethanol overnight. On the following day,
tissues were dehydrated in a graded ethanol series, cleared in xylene, and embedded into
paraffin wax (Fisher Scientific).
Five J...lm sections of paraffin embedded tissue were cut using a microtome and placed
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onto microscope slides (Fisher Scientific). Sections were de-paraffinized for 10 minutes in
three changes of xylene, and hydrated through a graded alcohol series (100%, 95%, 70%)
into tap water and stained using hematoxylin and eosin. Briefly, hydrated sections were
stained in Mayer's hematoxylin for 5 minutes, rinsed in two changes of tap water, dipped in
0.25% ammonia water until sections were blue, rinsed in tap water again, and stained with
Johns Hopkins eosin for 15 seconds. Tissue sections were then dehydrated using
successively two changes of 95% ethanol, two changes of 100% ethanol, and three changes
of xylene before coverslipping.

V. Transmission Electron Microscopic Evaluation of Tumor Tissue and Cell Cultures
Either primary CMN or CCSK tumor tissue was removed and cut into 1 mm3
fragments and fixed in 2.5% sodium cacodylate buffered glutaraldehyde as the primary
fixative overnight. On the following day, tissue fragments were rinsed in O.IM cacodylate
buffer and post-fixed in 2% (w/v) osmium tetroxide in 0.1 M PBS for one hours at room
temperature. The tissue was then successively dehydrated in a graded ethanol series and
placed in two changes of propylene oxide for ten minutes each at room temperature before
infiltration in a series of propylene oxide and Epon 812 (50% propylene oxide/50% epon
resin for one hour, 25% propylene oxide/75% epon resin for one hour, and 10% propylene
oxide/95% resin for one hour, all at room temperature). Finally, tissues were embedded into
pure Epon 812 resin. Resin was allowed to polymerize overnight at 70° C before cutting.
Epon blocks containing tissue fragments were cut into 100-150 nm sections using an
ultramicrotome. Sections were placed onto copper grids (Electron Microscopy Sciences). For
transmission electron microscopic (TEM) analysis, sections were stained with uranyl acetate
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(15g uranyl acetate in 25 ml of absolute methanol) and lead citrate (30 ml Milli-Q water,
1.33g lead citrate, 1.76g sodium citrate, and 8.0 ml of 4% sodium hydroxide). TEM
micrographs at various magnifications were obtained using a JEOL 100S Transmission
Electron Microscope (JEOL, Peabody, Massachusetts).
Cell cultures were fixed in situ and treated as described above. Exceptions to the
above mentioned protocol include substitution of 100% ethanol instead of propylene oxide
in the infiltration steps. Sections of the cell monolayer were also stained with uranyl acetate
and lead citrate as above. Electron micrographs were also generated similarly.
VI. Scanning Electron Microscopic (SEM) Evaluation of Tumor Cell Cultures

CCSK and CMN tumor cells were plated directly onto Thermanox sterile coverslips
(Electron Microscopy Sciences) and treated for 24, 48, or 72 hours in the presence of 1.0
J.lM all-trans retinoic acid. Cells were fixed in 2.5% cacodylate buffered glutaraldehyde for
1 hour at room temperature, rinsed in O.IM cacodylate buffer, and post-fixed in 2%(w/v)
osmium tetroxide. Coverslips were then rinsed briefly in distilled water and dehydrated in
an ethanol series before immersion in hexamethyldisilizane for five minutes at room
temperature as previously described (Kuhnel et ai., 1989). Hexamethyldisilizane treatment
was substituted for critical point drying. After air drying at room temperature for 30 minutes,
coverslips were mounted onto an SEM stub, sputter coated with carbon using a Polaron
Equipment SEM Coating Unit E5150 (Electron Microscopy Sciences) and visualized using
a JEOL JSM-541 OL V Scanning Electron Microscope (JEOL).
VII. Initiation of Tumor Cell Culture

Primary tumor tissue obtained from the Surgical Pathology division of the MUSC
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Department of Pathology and Laboratory Medicine and the Department of Pathology at
Wake Forest University School of Medicine or tissue derived from nude mouse
heterotransplants was maintained in DMEM supplemented with 15% fetal calf serum until
time to initiate a cell culture. Tissue was minced within a few hours into small pieces of
about 2-5 mm and placed into a tissue culture flask coated with Type I collagen (Collagen
Corporation, Palo Alto, California, USA) and fetal calf serum (Gibco BRL) until tumor
fragments were attached to this substrate (approximately thirty minutes). Alternatively,
tumor tissue was minced very finely and subjected to tissue dissociation in type I
collagenase, 200 units/mg of dry weight and deoxyribonuclease, 400 units/mg of dry weight
(both from Sigma Chemical Company). Both collagenase and deoxyribonuclease were
solubilized in Hank's Balanced Salt Solution (HBSS) (Gibco BRL) to a final concentration
of 1.4 mg/ml of collagenase and 1.0 mg/ml of deoxyribonuclease. Tissue was completely
covered with this solution and subjected to dissociation in a trypsinization flask for 15
minutes at 37° C.
The cell suspension was the filtered through sterile 90J.lm-mesh diameter nylon
filters. The filter was then rinsed several times in HBSS. The filtrate was subjected to
centrifugation at 180 g at 4° C for 8 minutes in a Sorvall RT6000D centrifuge (DuPont,
Newton, Connecticut, USA) in order to obtain a cell pellet. The cell pellet was then
resuspended in a small volume of media before plating into a Coming tissue culture flask
(Fisher Scientific).
Both CMN and CCSK cultures were plated into media with the following
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characteristics: a 1:1 combination ofDMEM and Ham's F-12 (FI2) medium (both from
Gibco BRL) prepared using water from a Milli -Q water purification system and subsequently
filtered through a 0.2}lm sterile filter unit (both from Millipore Corporation, New Bedford,
Massachusetts, USA). Media was stored at 4° C until use. To prevent fungal or bacterial
growth, penicillin (final concentration of 100 U/ml), streptomycin ( final concentration of
100U/ml),and amphotericin B (final concentration of 2 mg/ml) was added to media.
Penicillin, streptomycin, and amphotericin B were acquired from Gibco.
At the time of use, the latter combination ofDME and F12 was supplemented with
insulin (5}lg/ml), transferrin (5}lg/ml), selenium (5J.lg/ml), hydrocortisone (36 ng/ml), and
triiodothyronine (4pg/ml)(Collaborative Research, Lexington, Massachusetts, USA) as
previously described (Hazen-Martin et al., 1994) and either 2%, 10%, or 20% fetal calf
serum (v/v). Cells maintained in T75 Coming tissue culture flasks received 15 ml and T25
Coming tissue culture flasks received 5 ml of media. Media were replaced every other day
during the propagation of these cells. Cells were maintained in a 5% C0 2195% air incubator.
Confluent cell cultures in T75 Coming tissue culture flasks were sub-cultured by
rinsing the cell monolayer with phosphate-buffered saline (PBS), pH 7.3 followed by the
addition of 3.0 ml of 0.05% trypsin-O.02% EDTA (Gibeo BRL). Cell detachment was
monitored using an inverted phase contrast microscope. Once cells were released from the
substrate, trypsin was inactivated in an equal volume of fetal calf serum. Cells were
centrifuged in a 50.0 ml conical centrifuge tube at 180 g at 4° C for eight minutes. The
resulting cell pellet was resuspended in 2.0 ml - 5.0 ml of fresh media and plated into
additional Coming tissue culture flasks. Photomicrographs of cell cultures were recorded

47
using a Zeiss IM35 inverted microscope on 35 mm Kodak Panatomic X-film, ASA 32.
Cell cultures were routinely frozen for future use in their respective growth media
with 100/0 dexamethasone (Fisher Scientific). Frozen cell pellets were maintained in a liquid
nitrogen dewar until thawed for additional studies.

VIII. Cis-Diamminedichloroplatinum (II) (Cisplatin) DNA Damage Response Assay
CCSK-2, CCSK-BG 1, CMN-1, CMN-2, and the anaplastic Wilms' tumor cell lines
W4 and W16 were plated at subconfluence in type I collagen coated T25 Coming tissue
culture flasks (Fisher Scientific). Cells were subsequently exposed to 1 x 10-4 M cisplatin
(Platinol™, Bristol-Meyers-Squibb, Princeton, New Jersey, USA) diluted in their respective
growth media for 2, 4, 6, 8, 10, and 20 hours and maintained at 37°C in a 95% air/5% CO 2
incubator. Control groups did not receive cisplatin. Cells from each time point were collected
by trypsinization and total cellular RNA and protein was extracted. RNA was
electrophoresed and transferred to nitrocellulose before probing with cDNA probes specific
for p21, Bax, p53, and MDM-2 genes. Protein was resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and electroblotted onto nitrocellulose before probing with
p53 and p21 monoclonal antibodies. Cells were also collected for flow cytometric
determination of G-l cell cycle arrest and apoptosis.

IX. All-trans Retinoic Acid Induced Cell Differentiation Assay
CCSK-2, CCSK-BG1, CMN-l, CMN-2, and SK-N-SH neuroblastoma cells
(American Type Culture Collection, Rockville, Maryland, USA) were plated at
subconfluence in type I collagen coated Coming T25 tissue culture flasks (Fisher Scientific).
Cells were subsequently exposed to 1 x 10-6 M atRA for 24, 48, and 72 hours in the dark at
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37°C in a 95% air/ 5% CO 2 incubator. Control cells were treated similarly excepting atRA
treatment. At each time point, cells were photographed using a Zeiss inverted phase contrast
microscope, fixed for both transmission and scanning electron microscopy, and lysed for
RNA extraction.

x. Immunocytochemistry Using Peroxidase Labelled Secondary Antibodies
Cells were plated very sparsely onto Lab-tek chamber slides (Nunc Incorporated,
Naperville, Illinois, USA) coated with type I collagen and fetal calf serum as previously
described for Coming tissue culture flasks. Cells were then fixed for 10 minutes at room
temperature in 3.7% formaldehyde in PB S, pH 7.3 or Camoy' s solution. Subsequently, cells
were rinsed in 70% alcohol, if fixed in formaldehyde, or 100% alcohol, if fixed in Camoy' s
solution. Before staining, cells were rinsed several times in PBS, pH 7.3 and permeabilized
using 0.1 % Triton-X 100. Cells were again rinsed several times in PBS before blocking in
10% normal horse serum (Vector Laboratories, Burlingame, California, USA) for 30 minutes
at room temperature. Serum was then drained and cells were incubated in monoclonal
antibodies against p53 (clone DO-7, 1: 100 dilution), MDM-2 (1 :50 dilution), smooth muscle
actin (1 :75 dilution), desmin (1 :50 dilution), AE1/AE3 cytokeratin (1 :50 dilution), or
vimentin ( 1:5 0 dilution) (N ovocastra Laboratories Ltd. ,Newcastle upon Tyne, Great Britain)
for one hour at room temperature. Cells were then rinsed three times for five minutes each
in PBS, pH 7.3. and incubated in horse anti-mouse antibody heavy and light chain (1:100
dilution) (Vector Laboratories). After rinsing three times for five minutes each in PBS, pH
7.3, cells were treated with avidin-biotin-horseradish peroxidase complex (ABC) provided
in a Vectastain Elite kit and stained using 3-3 '-diaminobenzidine (Vector Laboratories). Lab-
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teks containing the cells were then dehydrated in a graded ethanol series and xylene and
coverslipped before microscopic visualization.
Frozen tumor tissue was embedded in OCT frozen tissue embedding media (Lab-Tek,
Arlington Heights, Illinois), cut at 5 J.lM in a cryostat, briefly allowed to adhere to a
microscope slide, and fixed in neutral buffered formaldehyde for one minute at room
temperature. Tissue sections were then rinsed in PBS, and treated in the same manner as cells
on Lab-teks.
Paraffin embedded tissue was cut at 5 mM, deparaffinized in three changes of xylene,
incubated in PBS, and finally 10% normal horse serum. The remaining protocol is the same
as that used for cells.

XI. Immunofluorescence Cytochemistry
Cells were plated very sparsely onto 35 mm dishes coated with type I collagen and
fetal calf serum as previously described for Coming tissue culture flasks. Cells were then
fixed for 10 minutes at room temperature in 3.7% formaldehyde in PBS, pH 7.3 or Camoy's
solution. Subsequently, cells were rinsed in 700/0 alcohol, if fixed in formaldehyde, and
100% alcohol, if fixed in Camoy's solution. Before staining, cells were rinsed several times
in PBS, pH 7.3 and permeabilized using 0.1 % Triton-X 100. Cells were again rinsed several
times in PBS before blocking in 10% normal horse serum (Vector Laboratories) for 30
minutes at room temperature. Serum was then drained and cells were incubated in
monoclonal antibodies against p53 (clone DO-7, 1: 100 dilution), smooth muscle actin (1 :75
dilution), desmin (1 :50 dilution), AEI/AE3 cytokeratin (1 :50 dilution), and vimentin (1 :50
dilution) (Novocastra) for one hour at room temperature. Cells were then rinsed three times
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for five minutes each in PBS, pH 7.3. and incubated in rhodamine labelled goat anti-mouse
antibody(l: 100 dilution)(Jackson ImmunoResearch, West Grove, Pennsylvania) for 30
minutes at room temperature in the dark. Cells were then briefly rinsed in PBS and mounted
in 10% glycerol in PBS, pH 7.3 before visualization with a Zeiss epifluorescence
mIcroscope.

XII. Flow Cytometry Cell Cycle Analysis
Approximately 1 x 106 cellsfromculturesofCMN-l, CMN-2, CCSK-2, CCSK-BGl,
W4, and W16 were plated into collagen and fetal calf serum coated Coming T25 flasks
(Fisher Scientific) and incubated overnight at 37°C in a 5% C0 21 95% air incubator. On the
following day, cells were treated with 100 J.lM cis-diamminedichloroplatinum (BristolMeyers-Squibb for 4, 8, and 20 hours. At each time point, cells were trypsinized in 0.05 %
trypsin, 0.53M Ethylenediaminetetracetic acid (Gibco).Preparation of cells for flow
cytometry was performed essentially as previously described (Schandl, et aI., 1997). Briefly,
cisplatin treated cells were centrifuged after trypsinization at 1000 RPM for 10 minutes at
4°C, rinsed in PBS, pH 7.3, and centrifuged again at 1000 RPM for 10 minutes at 4°C. Cells
were then fixed in 1% formaldehyde for 10 minutes on ice and then rinsed and centrifuged
as before. Cells were maintained overnight in 80% ethanol at -20°C before staining. On the
following day, cells were rinsed and centrifuged two times in PBS, pH 7.3. Cells were finally
stained with propidium iodide staining solution (0.01 J.lg/ml propidium iodide, 0.01 Kunitz
units RNase I J.lI in PBS, pH 7.3) for 30 minutes in a dark location. 1 x 104 Cells were then
measured in an EPICS XL-MCL Four-Color Analytical Flow Cytometer (Coulter
Corporation, Miami, Florida, USA) and analyzed using Phoenix Multicycle Software.
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XIII. Protein Gel Electrophoresis and Western Blotting

Cell cultures of CMN, CCSK, and anaplastic Wilms' tumors treated with cisdiamminedichloroplatinum (Bristol-Meyers-Squibb Pharmaceuticals) were extracted in
Laemmeli buffer (0.0625 M Tris-CI pH 6.8, 2% sodium dodecyl sulfate, 5%
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mercaptoethanol, 10% glycerol, and 0.002% bromophenol blue)( Laemmeli,1970) . Equal
amounts of protein were then electrophoresed in a 11 % acrylamide (30:0.8 acrylamide: bisacrylamide) gel at 90 V in Tris-glycine buffer at room temperature for approximately 21/2
hours. Subsequently, the polyacrylamide gel was electroblotted overnight at 4°C at 35V in
protein transfer buffer (20% methanol in tris-glycine buffer) onto a Transblot 0.2Jlm
nitrocellulose membrane (BioRad,Hercules, California, USA).
Nitrocellulose membranes were then blocked in 5% Carnation skim milk, 0.05%
Tween 20 (Blotto) for 15 minutes at room temperature. Blotto was then removed and the
membrane was probed with a p53 mouse monoclonal antibody, clone DO-7 (1 :5000 dilution)
(Novocastra) or a 1:500 dilution of p21 cipl mouse monoclonal antibody (Transduction
Laboratories, Lexington, Kentucky, USA) in Blotto/0.05% Tween 20 for one hour at room
temperature. Membranes were then rinsed three times,each for five minutes in PBS/O.05%
Tween 20 and incubated with al :7500 dilution of horseradish peroxidase conjugated goat
anti-mouse antibody (Jackson ImmunoResearch) for 30 minutes at room temperature.
Nitrocellulose membranes were finally rinsed three times, for five minutes each time, and
developed using enhanced chemiluminescence (ECL reagents) according to manufacturer
instructions (Amersham, Buckinghamshire, England). Membranes were then exposed to
Kodak X-OMAT film (Sigma Chemical Company) and developed using a automatic
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developer (Konica Corporation, Japan).
XIV. RNA Extraction-Agarose Gel Electrophoresis-Northern Blotting

RNA was extracted from either snap fozen primary tumor (and/or resulting tumor
heterotransplants) or cultured cells essentially as previously reported (Chomczynski et al ,
1987). Fresh frozen tissue was pulverized into a fine powder using a mortar and pestle under
liquid nitrogen. After evaporation of liquid nitrogen, the tissue was lysed in 5.0 ml of
denaturing solution (4M guanidinium isothiocyanate, 25mM sodium citrate pH 7.0, 0.5%
sarcosyl, 0.1% B-mercaptoethanol, 0.02% sodium azide). The resulting solution was then
acidified using 500 J.lI 2M sodium acetate, pH 4.0 and extracted in phenol equilibrated with
water, 0.1 % hydroxyquinoline, and 0.2% mercaptoethanol, and 49: 1 chloroform: isoamyl
alcohol solution. After mixing into a homogeneous emulsion, the sample was centrifuged at
4000 g for thirty minutes at 4°C. The resulting aqueous phase was then removed and
transferred into another tube and re-extracted in a 1: 1 solution of phenol and chloroform,
mixed into an emulsion, and centrifuged at 4000 g for 30 minutes at 4°C. The aqueous phase
was again removed and precipitated in cold absolute ethanol overnight at -20°C. On the
following day, the latter sample was centrifuged at 3500 g for thirty minutes at 4°C. The
resulting RNA pellet was then rehydrated in 200 J.lI of water followed by the addition of200
J.lI of Buffer A (0.4 M sodium chloride, 10mM Tris pH 7.4, 5mM ethylenediaminetetracetic
acid, 0.1 % sodium dodecyl sulfate) and re-precipitated in cold absolute ethanol for two
hours at -80°C or overnight at -20°C in an Eppendorftube. The sample was the centrifuged
at 10000 g for 10 minutes at 4°C. The resulting pellet was then rinsed once in cold 70%
ethanol and centrifuged again at 10000 g for 5 minutes, dried, rehydrated in water, and
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concentration measured in a spectrophotometer (Beckman Instruments, Fullerton, California,
USA).
Aliquots of 5f.1g of RNA was loaded into each lane of a 1.2% SeaKem agarose (FMC
BioProducts,

Rockland,

Maine,

USA)-5

%

formaldehyde-IX

3-[N-morpholino]

propanesulfonic acid gel and was resolved by electrophoresis at 55 V at room temperature.
To visualize the integrity of the 28S and 18S rRNA species along with smaller RNA
molecules and determine loading efficiency, the ethidium bromide stained gel was photoed
for permanent records. The gel was then transferred to a 0.2 mm nitrocellulose membrane
(BioRad Laboratories) overnight in the presence of lOX SSC using a technique previously
described (Southern, 1975). After transfer, the nitrocellulose membrane was baked at 88°C
for 1 Y2 hours in a Napco vacuum oven model 5831 (Precision Scientific, Chicago Illinois)
and kept in a 4°C cooler until hybridization.

xv. cDNA Probe Labelling and Nucleic Acid Hybridization
cDNA fragments ofWT-l, p53, p21, MDM-2, IGF-2, BP-2, MDR-1, Pax-2, Pax-8,
glyceraldehyde phosphate dehydrogenase (GAPD), Bcl-x, Bax, and Tenascin genes were all
labelled using a Random Primed DNA Labelling Kit according to manufacturer instructions
(Boehringer-Mannheim, Indianapolis, Indiana, USA). p53, p21, IGF-2, and GAPD cDNA
probes were acquired from the American Type Culture Collection. The MDM-2 probe was
a gift from Dr. Bert Vogelstein (Johns Hopkins University) and the Tenascin cDNA probe
was provided by Dr. Maria Trojanowska (Department of Rheumatology , Medical University
of South Carolina). The random priming method of DNA labelling has been previously
reported (Feinberg et al., 1987) Briefly, 25 ng of DNA was boiled for 3 minutes, quenched
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on ice, and incubated for one hour at 37°C with 3 f.ll of an equimolar nucleotide mixture (A,
T, and G), 5 JlI of 10IlCi/1l132P-adCTP (ICN Pharmaceuticals), 2JlI of random hexamers,
and I f.ll ofKlenow enzyme (total reaction volume = 20 Ill). Labelled DNA was then purified
using Sephadex (fine) G50 Spin columns per manufacturer procedure (BoehringerMannheim) and ethanol precipitated for one hour at -20°C in the presence of cold DNA
carrier. DNA was then pelleted by centrifugation at 10000 g for 10 minutes at 4°C. The
pellet was washed once in 75% ethanol and centrifuged as before. The DNA pellet was then
rehydrated in 200 III of distilled water and 40 f.ll was counted in a scintillation counter
(Beckman Instruments). The specific activities of probes used were between 1.5 and 2.0 x
109 cpm/ Ilg.
A total of 0.8 x 106 cpm of labelled probe per milliliter of hybridization solution
(40% formamide, 2.0X SSC, 40mM sodium phosphate, pH 8.0, 200 ug ml sheared salmon
sperm DNA) was employed in all experiments. Before hybridization, nitrocellulose filters
were pre-wetted for approximately 30 minutes in hybridization solution. The volume of
hybridization solution used was determined using 0.08 ml/cm2 of membrane as a reference.
Nitrocellulose filters were incubated overnight at 52°C in hybridization solution.
Nitrocellulose membranes were then washed twice (5 minutes each) at room temperature in
2.0X SSe/O.I % SDS and twice (15 minutes each) at 54°C in O.IX SSC/0.1 % SDS, dried, and
exposed to X-ray film. Autoradiograms were quantified using Adobe Photoshop version 4.0
software.
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XVI. p53 Polymerase Chain Reaction (PCR)- Single-Stranded Conformation
Polymorphism (SSCP) and DNA Sequencing
SSCP was performed following methods previously described (Orita et al , 1989;
Baird et al., 1992). An aliquot of 1.0 Ilg of total cellular RNA was first reverse transcribed
using an RNA PCR Kit (Perkin-Elmer, Norwalk, Connecticut, USA) and further amplified
using the following sets of primers specific for exons 2 - 11 of the human p53 gene as
previously described (El Bahtimi et al., 1996):

exons 2-4: sense: 5' GACGGTGACACGCTTCCCTGGATT
antisense: 5' CATCTTGTTGAGGGCAGGGGAGTA;

exons 5-6: sense: 5' ACAGCCAAGTCTCTGACTTGCACG;
antisense: 5' GATGGTGGTACAGTCAGAGCCAAC;

exons 7-9: sense: 5' GTGGTGCCCTATGAGCCGCCTGAG
antisense: 5' CTCGAAGCGCTCACGCCCACGGAT;

exons 10-11: sense: 5' GATGGAGAATATTTCACCCTTCAG;
antisense: 5' TCAGTGGGGAACAAGAAGTGGAGA.
The peR mixture contained 10 pmol of each primer set, 2 nmol of each nucleotide (A,G,
and T), 0.25 U Taq Polymerase, 10 III of buffer specified in the RNA PCR Kit, and 1.0 III
10 a_32 p dCTP ( 10 IlCi/IlI, ICN Pharmaceuticals). Thirty cycles of amplification were
performed using the following settings on a 9600 Perkin-Elmer Thermocycler: 94°C for 0.5
minutes, 55°C for 0.5 minutes, and 72°C for 1 minute. A 1.0 III aliquot of the reaction
mixture was withdrawn and mixed with 100 III of 0.1 % SDS/ 10mM EDTA. Then 2.0 III of
the latter solution was mixed with 2.0 Jll of SSCP loading buffer (95% formamide, 20 mM
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EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol). The resulting solution was
heated to 80 D C before loading 1.0 ml of sample into a 6% polyacrylamide gel (90 mM Trisborate, pH 8.3, 4mM EDTA, and 10% glycerol).Control samples were not heated at 80 DC
before loading. Samples were electrophoresed for 3 hours at 30 W with the use of a cooling
fan. After electrophoresis, the gel was dried on filter paper and exposed to X-ray film.
PCR products demonstrating a mobility shift by SSCP analysis were subjected to
DNA sequencing on both strands using the appropriate primer set using a Sequitherm DNA
Cycle Sequencing Kit (Epicentre Technologies, Madison, Wisconsin, USA). The latter is
based upon the dideoxy chain termination sequencing method previously described (Sanger

et al., 1977). Either 32 P- or 35S-a-dATP was employed in all sequencing reactions.
Sequencing reactions were performed in a Perkin-Elmer 9600 thermo cycler using the
following settings: 95 DC for 5 minutes, 95 DC for 30 seconds and 70 DC for 1 minute for 30
cycles and held at 4DC indefinitely. Sequencing reaction products were electrophoresed in a
6% acrylamide denaturing gel (7M Urea, 4.5 ml of 40% acrylamide, 3.0 mIl OX TBE, 0.248
ml 10% ammonium persulfate to a final volume of 30.0 ml with distilled water, and 19 JlI
TEMED) at 1200 V, constant wattage. Gel was then fixed in for 30 minutes in 5% acetic
acid! 15% methanol, affixed to Whatman filter paper, dried for 30 minutes in a Gel dryer
(BioRad Laboratories), and exposed to X-ray film.

Chapter 3
Morphological and Molecular Characterization of an In vitro and In vivo Model
for the Study of Clear Cell Sarcoma of the Kidney and Cellular Congenital Mesoblastic
Nephroma

I. Introduction
Clear cell sarcoma of the kidney (CCSK) and congenital mesoblastic nephroma
(CMN) together comprise 10% of all pediatric renal neoplasms (Murphy et aI., 1994). CCSK
and CMN differ from the more common Wilms' tumor, or nephroblastoma, in histology and
clinical behavior. CCSK was first delineated from Wilms' tumor in 1970 as a potentially
aggressive tumor which has a propensity for metastasizing to bone in some patients (Kidd,
1970). Thus, some have stressed the diagnostic distinction of this tumor from the relatively
benign classical, or triphasic Wilms' tumor (Beckwith et al., 1978;Marsden et al., 1978;
Morgan et al., 1978). Contrasting with the clinicopathological features of CCSK, CMN is
generally a benign tumor of neonates primarily occurring within the first three months of life
(Bolande et al., 1967). CMN may be subdivided into the classical and cellular variants.
Cellular CMN has a tendency to recur and metastasize in some instances ifnot completely
resected (Joshi et al., 1986). Because both of these tumors demonstrate signs of stromal
differentiation, some have suggested that CMN, particularly cellular CMN, may represent
the benign counterpart ofCCSK (Beckwith et al., 1978). The latter suggests a relationship
similar to that suggested for classical and anaplastic Wilms' tumors (Re et al., 1994;
Bardeesy et al., 1994). Nevertheless, the histogenetic origins of these two tumor types, their
molecular genetic relationships with each other, and relationships with Wilms' tumor still
remain largely unknown.
The vast majority of the available literature on CMN and CCSK has been limited to
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morphological studies. CCSK is histologically characterized by the the presence of empty
appearing nuclei, abundant collagenous extracellular matrix material, and a fine arborizing
pattern of blood vessels easily recognized using Ulex Europeaus agglutinin staining (Mierau
et a/., 1989). In some forms, CCSK may be confused with other pediatric renal tumors. For

example, CCSK may mimic the blastemal predominant Wilms' tumors, congenital
mesoblastic nephroma, and osteosarcoma. Immunohistochemistry has provided little
information regarding the origins of CCSK. One report has indicated no reactivity for
fibronectin, laminin, and epithelial membrane antigen in all tumors examined (Kumar et a/.,
1986). Another study indicated that CCSK was positive for vimentin, a marker for
mesenchymal cells, but non-immunoreactive for epithelial membrane antigen, von
Willebrand factor, desmin, S-100 protein, and Mac387 in eight cases examined (Looi et a/.,
1993). In contrast, Wilms' tumor cases in the same report were positive for epithelial
membrane antigen (in areas of tubular differentiation) and vimentin (in the glomeruloid
bodies and stromal cells). Ultrastructural studies of CCSK indicate the near absence of
heterochromatin in tumor cell nuclei, few intracellular organelles, and collagen deposition
in the extracellular matrix (Haas et a/., 1984). Molecular studies of CCSK are extremely
limited. One report examined the mRNA expression of the Wilms' tumor suppressor, WT-J,
and the insulin-like growth factor II (IGF-2) in CCSK. In contrast to Wilms' tumors, CCSK
did not express WT-J while IGF-2 mRNA levels were high in the same cases in a report of
two cases (Yun, 1993).
Two histologically distinct forms of CMN exist: classical and cellular (or atypical).
Classical CMN is composed of interlacing bundles of spindled mesenchymal cells with
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moderate cellularity and mitotic activity. Cellular CMN, in contrast, is typically composed
of larger cells with hyperchromatic nuclei and greater mitotic activity in a denser cellular
array (Murphy, 1994). The diagnosis of cellular CMN is sometimes problematic due to its
resemblance to other renal neoplasms including monophasic blastemal Wilms' tumor,
CCSK, and the R TK. Immunohistochemical studies of both CMN variants have exhibited
staining for vimentin, desmin, and actin. No reactivity was reported for S-100, cytokeratin,
epithelial membrane antigen, and Leu7 proteins in these tumor types (Pettinato et al., 1989).
Ultrastructurally, cellular CMN is characterized by the presence of prominent rough
endoplasmic recticulum and bands of peripheral cytoplasmic filaments. Ultrastructural
analysis has not, however, provided a clear definition of the cellular derivation of these
tumors.
The biological relationships between CCSK, CMN, and Wilms' tumors are
enigmatic. The study of CCSK, CMN, and their relationship with Wilms' tumor has been
particularly hindered by the relative rarity of both of these tumor types. In this study, we
report the development of both a cell culture and nude mouse xenograft model system for the
study of CMN and CCSK. Both cultures and xenografts have been surveyed for their light
and electron microscopic features and gene expression profile at the immunohistochemical
and mRNA level. We report that nude mouse xenografts and cell cultures maintain cellular
and molecular characteristics of the corresponding primary tumors in most instances. In some
CCSK cell cultures, immunocytochemical changes were noted, however, which may have
implications for tumor histogenesis.
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II. Results
1. In vitro Characteristics of CCSK and CMN
Cell cultures of CMN and CCSK were successfully established from nude mouse
xenograft tissue and primary tumor tissue, respectively. Tumor tissue was minced into
fragments and placed into a type I collagen and fetal calf serum coated tissue culture flask
with approximately 5 milliliters of fetal calf serum-containing growth medium. Cellular
outgrowth from fragments was noted in cultures within one week. Phase microscopic
analysis revealed spindle-shaped cells in all cultures examined (Figures 1&2). Cellular
CMN-2 often demonstrated round to oval cells in addition to the presence of spindle shaped
cells (Figure 2B). In addition to the presence of cells with fibroblastic appearance, CCSK cell
cultures also contained focal areas of close cellular opposition (Figure 1). Table 1
summarizes this laboratory's experience with development ofCCSK and CMN cell cultures.

2. Light and Electron Microscopic Analysis of CCSK and CMN Nude Mouse
Xenografts
Primary tumor tissue from two cellular CMN and four CCSK were successfully
heterotransplanted into BALB/c athymic (nude) mice. After tumor volume reaches
approximately 8-12 cm3 , mice were sacrificed before removal of tumor and re-injection into

subsequent mice. At each passage, tumors were monitored for morphological changes using
hematoxylin and eosin (H&E) staining and transmission electron microscopic analysis.
Figure 3 summarizes the light microscopic findings of primary and xenografted CCSK and
CMN tumors. Figure 3A/A' and Figure 3BIB' correspond to H&E micrographs of cellular
CMN-l and CMN-2 xenografts, respectively. No CMN primary tumor tissue was available
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for comparison for either tumor. Figure 3A shows the close cellular opposition of tumor cells
in an early CMN-l mouse xenograft. Figure 3A' is an H&E micrograph ofCMN-l at nude
mouse passage 73. Figure 3B is from nude mouse passage 5 and Figure 3B' is from passage
56. Round to spindle cells with a slightly eosinophilic cytoplasm is a feature of both tumors
and remains consistent with the histology of cellular CMN tumors. Figure 3C/C' and Figure

3D/D' represent primary tumor specimens and xenografts of CCSK-2 and CCSK-BGl,
respectively. Hallmark cells with clear nuclei embedded within eosinophile collagenous
matrix material were characteristic of CCSK-2 and CCSK-BG 1 primary and xenografted
tumors. Both CCSK-BG 1 primary tumor and xenograft contained rosette formation as well.
In all cases, tumor histology between primary tumor and xenograft was maintained. Tumor
xenograft growth characteristics are summarized in Table 1.
Representative transmission electron microscopic analysis ofCCSK-2 and cellular
CMN-l xenograft was also conducted. Ultrastructurally, both CCSK-2 primary tumor and
xenograft were characterized by cell nuclei nearly devoid of heterochromatin with a small,
single nucleolus present in most cells. A few, small mitochondria with rough endoplasmic
recticulum comprise features of the cytoplasm (Figure 4 A&B). Desmosomaljunctions were
noted in CCSK-2 primary tumor. CCSK-2 xenograft also demonstrated deposition of
collagenous matrix material between cells, a characteristic finding of primary CCSK tumors
(Figure 4B). CMN-l early xenograft demonstrated cells with nuclei containing a single
nucleolus with moderate amounts of heterochromatin. Tumor cell cytoplasm was
characterized by the presence of few mitochondria and sparse rough endoplasmic recticulum
(Figure SA).

63
CCSK-2 and cellular CMN-lcell cultures were also examined ultrastructurally.
CMN-l cells grew in sheets while maintained on a type I collagen growth surface and
maintained the same bland nuclear and cytoplasmic features of its corresponding xenografted
tumor. A single desmosomal junction is noted in Figure SB. CCSK-2 cells also grew in
sheets while maintained on a collagen growth surface. Tumor cells were characterized by
empty nuclei, prominent rough endoplasmic recticulum, close interdigitation, an the presence
of intermediate filaments. There was no evidence for collagenous matrix production by
CCSK-2 cells (Figure 4C). CCSK-BGI cells were characteristically similar.

3. Immunofluorescent Cytochemical Analysis of Intermediate Filament Proteins in
CCSK and CMN Cells
To gain a better understanding of the cellular derivation of both CCSK and CMN,
tumor cells were evaluated using mouse monoclonal antibodies to desmin, smooth muscle
actin (SMA), vimentin, and cytokeratin intermediate filaments. Both cell cultures derived
from CCSK-2 and CCSK-BG 1 did not reveal any desmin or cytokeratin filament staining
(Figure 6). However, both of these cultures were positive for both vimentin and SMA.
OVCAR ovarian carcinoma cells were included as a positive control for cytokeratins and
negative control for muscle specific desmin and actin.
CMN cells derived from xenograft material (primary tumor tissue was unavailable)
demonstrated a variable immunochemical profile. CMN-l cells were positive for desmin,
vimentin, but only focally positive for SMA (Figure 7). In contrast, CMN-2 cells reacted only
with the vimentin monoclonal antibody. TB208 cells derived from an extrarenal malignant
rhabdoid tumor were included as a positive control for vimentin protein. OVCAR cells were
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again included as a negative control for muscle cell markers.

4. WT-l and IGF-2 Northern Analysis
To further evaluate the retention of primary tumor features in our in vivo and in vitro
models, we evaluated their gene expression profile. WT-J and IGF-2 are both genes which
are highly expressed during fetal kidney development and in Wilms' tumor. Comparative
mRNA expression analysis of these two genes was performed in CMN-l, CMN-2, CCSK-2,
and CCSK-BG1 primary tumors, xenografts, and cell cultures alongside primary Wilms'
tumors and normal kidney cells (Figure 8A). IGF -2 mRNA levels were similar in both CMN1 and CMN-2 primary tumors and xenografts. However, IGF-2 message was strongly
increased in their corresponding cell cultures. In contrast, CCSK-2 and CCSK-BG 1 mRNA
levels were higher in nude mouse xenografts compared to the corresponding primary tumor.
Few copies of IGF-2 message was detected in CCSK-BG 1 cultured cells, although
expression was unchanged in CCSK-2 cells. All primary Wilms' tumors, but not normal
kidney cell cultures, demonstrated IGF-2 mRNA.

WT-J mRNA was detected in both cellularCMN cases (Figure SB). In CMN-l, only
the primary tumor and cultured cells expressed detectable WT-J message. In contrast, WT-l
was expressed in CMN-2 primary tumor, xenograft, and cultured cells. All four classical
Wilms' tumors examined contained abundant WT-l transcripts. Normal kidney cell lines
lacked detectable WT-1 mRNA.
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III. Discussion
Study of the cellular and molecular biology of CCSK and CMN has been hindered
by the lack of a useful experimental model system. In addition to our lack of understanding
of the inherent genetic defects in CCSK and CMN, the relationship, if any, they share with
the more common classical Wilms' tumor remains unknown. In the present study, we have
demonstrated the successful establishment and characterization of cellular CMN and CCSK
tumor cell cultures and nude mouse xenografts that will be helpful in beginning to
understand the pathobiology of both tumors.
The histogenetic origin of both CCSK and CMN has been a debated topic for many
years. Previous reports have suggested that CCSK has a latent epithelial nature (Ishii et al.,
1989). This hypothesis derived from the observation of mucin production, cytokeratin
immunoreactivity, and the development of intracellular canaliculi in a series ofxenografted
and cultured CCSK tumors. That observation contrasts with the histological and
ultrastructural analysis ofxenografted and cultured CCSK tumors in this study as none of the
CCSK cases examined exhibited signs of epithelial differentiation as reported by Ishii
However, our cultured CCSK tumor cells did exhibit focal areas of close cellular opposition
possibly indicative of their epithelial potential. Nevertheless, immunocytochemical analysis
ofCCSK cell cultures in this study demonstrated reactivity with both SMA and vimentin but
not cytokeratin monoclonal antibodies. Vimentin, but not SMA, desmin, or cytokeratin
protein was detected in primary fixed tissue of CCSK consistent with prior reports (Looi et
al., 1993). Immunohistochemical data of CCSK cell lines and primary tumor tissue and

CMN celllines are summarized in Table2.
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The expression of SMA in our two CCSK cell lines suggests one of two possible
explanations. Firstly, the collagen matrix or plastic surface of tissue culture flasks may have
a differentiating effect on CCSK tumor cells. Contamination of CCSK cultures with normal
smooth muscle cells is unlikely. CCSK-2 and CCSK-BG 1 cell cultures demonstrate cells
growing in sheets that are relatively undifferentiated, a characteristic feature of tumor cells
only. In addition, lack of SMA immunoreactivity in CCSK primary tumors is not likely to
be due to fixation problems as arterial smooth muscle was stained. In any case, SMA
positivity in CCSK cells has not been reported in immunohistochemical analyses of these
tumors. Previous studies have reported no reactivity with epithelial membrane antigen,
fibronectin, laminin, desmin, and neural cell markers (Kumar et al., 1986; Looi et al., 1993).
CCSK cells were only reactive with vimentin monoclonal antibodies suggesting their
primitive mesenchymal nature. The hypothesis that CCSK cells are derived from
pluripotential stem cells has been further supported molecularly with the observation that
CCSK tumors lack WT-1 expression, a marker for induced renal mesenchymal tissue (Yun,
1993). In the present study, IGF-2 but not WT-l mRNA transcripts were detected in CCSK..
SMA positivity in CCSK cells may suggest that these cells have potential for differentiating
towards glomerular mesangial cells or arterial smooth muscle cells. Given the abundant
extracellular matrix deposition of CCSK and glomerular mesangial cells in pathologic
conditions, future studies evaluating CCSK cells with mesangial cell markers may be useful.
The histogenesis and pathobiology of cellular, or atypical CMN also remains
unresolved. The development of nude mouse xenografts that maintained the histologic and
ultrastructural appearance of their primary tumors made the development of cellular CMN
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cultures possible. Immunochemical characterization of resulting CMN tumor cell cultures
revealed desmin, vimentin, and SMA reactivity. These same cells did not react with
cytokeratin specific antibodies .. The latter findings are consistent with previous reports
which have documented immunoreactivity for these intermediate filament proteins (Pettinato

et al., 1989). These data are further suggestive of a smooth muscle derivation of CMN
tumors. Even though there is some overlap in the immunohistochemical profile ofCCSK and
CMN, Thy-l immunoreactivity has been reported in CMN, but not CCSK tissue which
further suggests that CCSK is derived from a more undifferentiated cell type (Hazen-Martin

et al., 1993).

Northern analysis of primary tumors, xeno grafts , and cell cultures

demonstrated the retention of gene expression characteristics between and among the two
cellular CMN examined. WT-l and IGF-2 were generally expressed in CMN primary
tumors, xenografts, and cell cultures. WT -1 expression was absent in two cases of CMN in
a previous report (Tomlison et al., 1992). The latter report did not identify the histologic
category ofCMN. The observation ofWT-1 in primary and xenografted cellular CMN in this
study is a novel finding. These data suggest that cellular CMN are relatively undifferentiated
tumors that may arise from cellular areas adjacent to the condensing renal mesenchyme.
Evaluation of the extracellular matrix protein tenascin, a marker ofuninduced mesenchymal
cells surrounding condensed mesenchyme may be useful in testing this hypothesis(Truong

et al., 1996).
Recent experiments in mice have reported expression of the BF -2 winged-helix
transcription factor in cells of the stromal lineage during fetal kidney development (Hatini

et al., 1996).In the same study, gene knockout studies ofBF-2 revealed that mesenchyme
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failed to differentiate into tubular epithelium. In light of these findings, it would be
interesting to evaluate both CCSK and cellular CMN xenografts for possible expression or
genetic alteration ofBF -2 as a means offurther comparing these tumors with different stages
of renal development. In addition, the CCSK xenograft and cell culture model system will
be useful in evaluating the role of p53 in the genetic etiology of this tumor as previous
immunohistochemical analyses ofCCSK has suggested the presence of mutations in these
tumors (Cheah et at., 1996). Finally, additional characterization of both CCSK and CMN
using the in vivo and in vitro model system reported here will not only provide a better
understanding of pediatric renal tumors, but also of the normal development of the stromal
cell lineage.
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Figure 1. Phase micrographs ofCCSK primary cultures plated on a type I collagen/fetal calf
serum substrate. A, CCSK-2 cells at 100X; A', CCSK-2 cells at 200X; B, CCSK-BG 1 cells
at 100X; B', CCSK-BG 1 cells at 200X. Black arrows indicate the stromal, or fibroblastic
appearance of some of the tumor cells. White arrows indicate a single nucleolus which is
characteristic of CCSK cells.
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Figure 2. Phase micrographs of CMN primary cultures plated on a type I collagen! fetal calf
serum substrate. A, CMN-1 cells at 100X; A', CMN-1 cells at 200X; B, CMN-2 cells at
100X; B', CMN-2 cells at 200X. The black arrow in A indicates one of the many mitotic
cells in this photomicrograph. The white arrow in B' indicates the round to elliptical cell
shape ofCMN-2 cells.
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Figure 3. Hematoxylin and eosin stained sections ofCCSK and cellular CMN primary tumor
tissue and nude mouse tumor xenografts. A, passage 1 of CMN-1 xenograft; A' , passage 73
of CMN-l xenograft; B, passage 1 of CMN-2 xenograft; B', passage 50 of CMN-2
xenograft; C, CCSK-2 primary tumor; C' passage 2 of CCSK-2 xenograft; D, CCSK-BG 1
primary tumor; D', passage 2 ofCCSK-BG1 xenograft. All micrographs at 250X.
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Figure 4. A, Transmission electron micrograph of CCSK-2 primary tumor tissue. Arrows
indicate primitive cellular junctions between two cells. N designates the cell nucleus which
is usually devoid of heterochromatin in CCSK. RER labels the rough endoplasmic
recticulum. B, Second passage of a CCSK-2 nude mouse xenograft with a nucleus containing
a single, prominent nucleolus. The arrow indicates collagenous matrix material which is
characteristic ultrastructural feature of CCSK. C, Early passage of a CCSK-2 cell culture
demonstrating the spindle shaped cells growing in layers. The arrow indicates intermediate
filaments within the cell cytoplasm. RER again marks the location of rough endoplasmic
recticulum. All micrographs at 12,500X.

c.
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Figure 5. A, Transmission electron micrograph of a CMN-I nude mouse xenograft. Cells

are round to elliptical and contain cell nuclei with heterochromatin and nucleoli (indicated
by large arrow). The cytoplasm is rather devoid of other organelles. B, Cell culture of a
CMN-l xenografted tumor demonstrating multilayers of cells. Nuclei of cells generally
contain a single, prominent nucleolus. The small arrow marks a cell junction between two
CMN cells.

A.

B.
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Figure 6. Immunocytochemical analysis ofCCSK primary cultures using mouse monoclonal
antibodies to desmin, smooth muscle actin (SMA), vimentin, and AEI/AE3 cytokeratin
intermediate filament proteins. OVCAR ovarian carcinoma cells are included as a positive
control for AEI/AE3 cytokeratin staining and a negative control for desmin and SMA
staining. Cells receiving no monoclonal antibody but incubated in secondary goat anti-mouse
antibody are indicated by omit.

CCSK-2

CCSK-BG1

OVCAR
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Figure7. Immunocytochemical analysis ofCMN-1 and CMN-2 cell cultures derived from
xenograft tissue using mouse monoclonal antibodies against desmin, SMA, and vimentin
intermediate filament proteins. TB208 cells were derived from an extrarenal malignant
rhabdoid tumor, a positive control for vimentin. OVCAR ovarian carcinoma cells are
negative controls for desmin and SMA. Cells that received no monoclonal antibody but were
incubated in secondary goat anti-mouse antibody are designated by omit.

CMN-1

CMN-2

TB208

OVCAR
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Figure 8. Northern analysis of primary tumor (P), xenograft (X), and cell culture (e) mRNA
using cDNA probes specific for: A, the WT-l tumor suppressor and B, the fetal mitogen
IGF -2. WT-1 expression is absent in most cases. Primary Wilms' tumors (W) were included

as a positive control for WT-l mRNA. Normal renal interstitial (RMIe), glomerular
mesangial (HMC), and kidney epithelial (PTe) cells were included as negative controls for
WT-l and IGF-2 mRNA expression.
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Table 1. Summary of CCSK and CMN Xenograft anf Cell Culture Characteristics
Tumor
Specimen

xenograft
turnover
time

current xenograft
passage num ber

cell cultures
derived

culture
growth
medium

subculture
frquency

CCSK-1

1 month

>90

no

N/A

N/A

CCSK-2

2.5 months

5

yes (primary
tumor and
xenograft)

2%FCS in
DMEIF12

2 weeks

CCSK-3

2.5 months

12

yes (xenograft

1 month

only)

2% FCS in
DMEIF12

CCSK-4

failure

N/A

N/A

N/A

N/A

CCSK-BG1

2.5 months

2

yes (primary
tumor and
xenograft)

20% FCS in
DMEIF12

2 weeks

CMN-1

1 month

> 80

yes (xenograft
only)

2% FCS in
DMEIF12

1 week

CMN-2

1 month

>60

yes (xenograft
only)

20/0 FCS in
DMEIF12

2 weeks

Chapter 4
Characterization of the p53 Signal Transduction Pathway in Clear Cell Sarcoma
of the Kidney, Congenital Mesoblastic Nephroma, and Anaplastic Wilms' Tumor

I. Introduction
Clear cell sarcoma of the kidney (CCSK) is a potentially aggressive renal neoplasm
of childhood with a proclivity for the development of bony metastases (Parham et al., 1996).
CCSK, first delineated from the more common Wilms' tumor in the 1970s (Kidd, 1970). This
tumor is distinguished from other renal tumors of childhood based on its more aggressive
clinical behavior and distinct histological characteristics including clear, empty appearing
nuclei and abundant extracellular matrix production (Kidd, 1970; Beckwith et al., 1978).
CCSK is classified by the National Wilms' Tumor Study in the same category as other
childhood renal tumors with poor prognosis including anaplastic Wilms' tumors and the
malignant rhabdoid tumor (Murphy et al., 1994). In contrast to CCSK, the congenital
mesoblastic nephroma (CMN) is a benign tumor which primarily affects neonates, usually
being diagnosed within the first three months of life. First described in the late 1960s, CMN
is a relatively benign tumor of the kidney which is usually cured with surgical resection
(Bolande et al., 1967; Wigger, 1969). CMNs may be further classified into the classical and
cellular (atypical) CMN based on histopathology and clinical behavior (Joshi et al., 1986).
In contrast to the wealth of molecular genetic knowledge concerning Wilms' tumorigenesis,
few reports exist describing the molecular basis for disease in CCSK and CMN. Some have
speculated, however, that CMN may represent the benign counterpart to the more malignant
CCSK (Beckwith, 1974).
Anaplastic Wilms' tumor (aWT) is another renal tumor affecting young children
which bears a poor prognosis. a WT is thought to develop as a result of a progression event
from the more common classical, or triphasic Wilms' tumor (Re et al., 1994; Bardeesy, et
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aI., 1994). Several studies have implicated mutations in the p53 tumor suppressor gene in the

development of anaplasia. In a comprehensive study of 140 Wilms' tumors, p53 mutations
were documented in 73% of tumors with anaplastic histology. The remaining 129 tumors
which did not exhibit morphological anaplasia lacked p53 mutations (Bardeesy et al., 1994).
Other reports have indicated that p53 mutations were associated with anaplastic tumors
which were invasive and metastatic (Lahoti et al., 1996). Additionally, EI-Bahtimi reported
p53 mutations in 67% of anaplastic tumors and no mutations in a series of classical tumors
examined (EI Bahtimi et al., 1996). Others have associated the presence of p53 mutations
in anaplastic Wilms' tumors with the development of the multi drug resistance phenotype.
One Wilms' tumor cell line, W4, bearing a homozygous p53 mutation overexpressed the
multi drug resistance (MDR-l) gene which codes for the P-glycoprotein, or multi drug
resistance transporter, an integral membrane ATP-dependent pump which prevents
accumulation of chemotherapeutic agents in the cytoplasm (Re et al., 1997). Therefore,
circumstantial evidence appears to support a role for p5 3 in the development of anaplasia and
resistance mechanisms in these tumors. Because CCSK is a potentially aggressive renal
tumor of childhood like aWT, it was hypothesized that abnormalities involving p53 are
implicated in CCSK umorigenesis. One report has indicated possible p53 mutation in a
series ofCCSK based on immunohistochemical p53 reactivity in a series of formalin fixed
paraffin embedded tumor specimens (Cheah et al., 1996). Neither cellular nor classical
CMNs have been evaluated for p53 immunoreactivity to date.
The p53 tumor suppressor is located on chromosome 17 and encodes a nuclear
phosphoprotein which acts via several signal transduction pathways to elicit either G 1 or
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G2/M cell cycle arrest, or apoptosis (Levine et al., 1991). Normally, p53 is induced following

exposure to ionizing or ultraviolet irradiation and chemotherapeutic agents (Ko et al., 1996).
The p53 protein mediates cell growth control by transcriptional modulation of a number of
effector genes which contain a consensus p53 binding site within their respective promoters.
The p21

wafllcipl

(p21) protein is a cyclin-dependent kinase inhibitor which is transactivated

by wild-type p53 protein to elicit cell cycle arrest (EI-Diery et al., 1994). This kinase
inhibitor is induced in cells that have sustained DNA damage by irradiation or exposure to
chemical agents (EI-Diery, et al., 1993). The p21 protein mediates cell cycle arrest by
binding to and inhibiting the kinase function of eyelin- cyclin dependent kinase complexes
and preventing phosphorylation of downstream proteins including the transcription factor Rb,
an event which frees the E2F transcription factor to positively regulate the transcription of
cyclins. In addition, p21 binds and inhibits the function of the proliferating cell nuclear
antigen, a protein controlling S-phase entry (Waga et al., 1994). In other reports, p53
mediates apoptosis by trans activating the pro-apoptotic gene Bax, a gene encoding a protein
with homology to Bcl-2 (Miyashita et al., 1995). Furthermore, studies have indicated that
wild-type, but not mutant, p53 molecules induced Bax expression (Zhan et al., 1994).
Transcriptional targets of p53 also include MDM-2, a gene which is amplified in some
sarcomas and is involved in negative regulation of p53 (Oliner et al., 1992; Momand et al.,
1992). The induction of MDM-2 by p53 after repair of DNA damage establishes an autoregulatory feedback loop (Wu et al., 1993; Burak et al., 1993). The status of these signal
transduction pathways controlled by p53 has not been investigated in CMN and CCSK
largely because cell lines derived from these tumors have not been established. This
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laboratory, however, has been successful in establishing both CMN and CCSK cell lines
which will be useful in evaluating the genetic mechanism(s) of disease in these two renal
tumors of childhood.
To evaluate the gene status and functional integrity of the p53 signal transduction
pathway in CCSK and CMN, we have evaluated both primary tumors and cell lines for
immunohistochemical expression of p53 protein in conjunction with gene structure analysis.
Furthermore, using cell lines, we have evaluated the functional state of p53 by the
transactivation ofp21, Bax, and MDM-2 in response to DNA damage following exposure to
cis-diamminedichloroplatinum (cisplatin), a chemotherapeutic agent known to generate single
and double strand breaks in DNA. Using Northern analysis, we also examined these tumors
for evidence of MDM-2 or MDR-l overexpression. We report that p53 protein is detectable
immunohistochemically in our CMN, but not our CCSK cell lines. However,
immunohistochemical analysis ofprimary CCSK and CMN tumors failed to demonstrate p53
protein immunoreactivity. Functional analysis of p53 in both CCSK and CMN cisplatin
exposed cell lines demonstrated transactivation ofp53 target genes including p21, Bax, and
MDM-2. In addition, MDM-2 was not overexpressed in any of the CCSK or CMN primary
tumors demonstrating that amplification or overexpression of this gene is not relevant to the
pathogenesis of these two stromal renal tumors of childhood.
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II. Results
1. p53 Immunochemistry, SSCP, and DNA Sequencing Analysis
Immunochemical staining of p53 is routinely used to screen for mutations of p53
(Esrig et at., 1993). Immunofluorescent staining ofp53 was evaluated in two CMN and two
CCSK cell lines developed in this laboratory using the mouse monoclonal antibody DO-7, an
antibody that recognizes both wild-type and mutant forms of the protein. Immunoreactive p53
was detected in both CMN cultures, but in neither of the CCSK cultures examined (Figure 1).
OVCAR ovarian carcinoma cells and the anaplastic Wilms' tumor celllineW16 harboring a
previously described p53 hotspot mutation were included as positive controls for p53 protein.
W4

anaplastic Wilms' tumor cells harboring a homozygous p53 mutation were not

immunoreactive with the DO-7 mouse monoclonal antibody.
To reconcile nuclear p53 staining in the CMN cell lines and its absence from CCSK
cells, a panel of CCSK and CMN primary tissues were examined using immunoperoxidase
methodology. Five fresh frozen tumors and four paraffin embedded tumors of CCSK
examined did not reveal nuclear p53 protein regardless of tumor stage (TableIA). Further,
examination of 3 cellular and 2 classical CMN failed to demonstrate nuclear reactivity.
Paraffin embedded tissue matching the immunoreactive cell lines also lacked demonstrable
p53 protein expression. An esophageal squamous cell carcinoma containing a previously
documented p53 mutation demonstrated nuclear activity and was used as a positive control.
CMN-l and CMN-2 cells, both demonstrating nuclear immunoreactivity for p53 protein, and
CCSK-2 cells were subjected to SSCP analysis to screen and direct DNA sequencing to
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confirm the identity ofp53 mutations (Table IB). No mutations were detected using primers
specific for exons 2-11 of the p53 gene in either of the two CMN cell lines.

2. mRNA Induction of Cisplatin Treated Tumor Cells
Both p53 immunochemistry and DNA sequencing fail to evaluate the function of the
p53 protein. In order to assess whether or not the function of this tumor suppressor was
impaired in the p53 immunoreactive CMN cell lines, we treated our cell lines with a DNA
damaging agent using an approach similar to previous experiments (0' Connor etal., 1997).
CCSK cells which were not reactive with the p53 protein were included as a
comparison.CMN-l, CMN-2,.CCSK-2, CCSK-BG1, anaplastic W4, and anaplastic W16 cell
cultures were treated for four and eight hours with 100 J..lM cisplatin and evaluated for their
induction of p21 and p53 using Northern analysis (Figure 2). Hybridization with a GAPD
cDNA probe was included as a control (Figure 2C). Both CMN and CCSK cell cultures
demonstrated induction ofp21 mRNA, compared to an untreated control (0 hours), over an
eight hour period (Figure 2A). Anaplastic W4 cells which are homozygously mutant for p53
failed to show p21 induction. Anaplastic W16 cells containing a point mutation at codon 273
in the p53 gene revealed a slight p21 induction over the same time period. In contrast to p21
induction, p53 mRNA levels remained unchanged in cisplatin treated CMN cells and declined
in both CCSK cell cultures (Figure 2B). p53 mRNA was undetectable in the W4 cell line and
declined over eight hours in W16 cells treated with cisplatin.
CMN-l, CCSK-2, and CCSK-BGI cells were further analyzed for the ability ofp53
to transactivate other target genes including Bax and MDM-2 over 20 hours exposure to
cisplatin using northern blot analysis (Figure 3 A&B). Hybridization of filters with p21 and
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p53 eDNA probes revealed, again, the upregulation ofp21 mRNA in all cell lines examined.
Whereas p21 induction begins at 2 hours in CMN -1 cells, increased levels of p21 mRNA are
not seen in CCSK-2 and CCSK-BG1 cells until 4 and 6 hours. p53 mRNA levels remain
stable early and decline late in all cell cultures examined (Figure 3 A&B). Induction of the 1.0
kb Bax-a mRNA was seen in CMN-1 and CCSK-2 cells. In contrast, Bax-a mRNA levels
declined in CCSK-BG 1 cells. Additionally, Bcl-X mRNA expression diminished with time
after cisplatin exposure (Figure 3C). MDM-2 expression was variable in both CCSK cell
cultures. CMN-1 cells revealed an initial increase ofMDM-2 mRNA at 2 hours exposure
before subsequently declining.
Quantification of p21, p53, MDM-2, Bax, and Bcl-X mRNA was performed to
establish the extent of gene expression modulation in CMN-1, CCSK-2, and CCSK-BG 1 cells
after exposure to cisplatin (Figures 4-7). In both CMN-l and CCSK-2 cells, p21 mRNA levels
increased three times after exposure to cisplatin. The strongest induction of p21 occured at
4 hours in CMN-l cells and at 10 hours in CCSK-2 cells (Figure 4). Expression ofp21 in
CCSK-BG 1 cells increased between four and six hours even though the extent of induction
was less than that demonstrated by CMN-l and CCSK-2 cells. In all cell lines, p53 mRNA
levels remained relatively stable or declined (Figure 5). Uniquely, CCSK-2 cells demonstrated
fluctuations in p53 gene expression over twenty hours of exposure to cisplatin even though
its expression did not exceed that of the control, or untreated cell culture. MDM-2 expression
was induced between two and four hours in CMN-l cells and between four and six hours in
CCSK-2 cells (Figure 6). MDM-2 expression declined in CCSK-BG 1 cells between two and
four hours before recovering at six hours. Measurement ofBax and Bcl-x was performed to
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determine the integrity ofthe apoptotic signalling pathway in CMN and CCSK cells. In CMN1 cells, Bax mRNA levels increased 1.5 times between two and eight hours after exposure to
cisplatin (Figure 7). Bax gene expression also increased by 2.5 times in CCSK-2 cells after
10 hours of cisplatin treatment. In both CMN-l and CCSK-2 cells, expression of the antiapoptotic gene Bcl-X decreased over twenty hours of treatment.

3. Stabilization of p53 Protein in Cisplatin Treated Cells
In the presence of a DNA damaging agent or irradiation, p53 protein is readily
stabilized in cells (Kastan et al., 1991). Due to p53-mediated trans-activation of p21,
increased amounts ofp21 protein also provide evidence for a functioning p53 molecule. To
evaluate p53 stabilization and p21 accumulation after exposure to cisplatin, protein extracts
were prepared from cisplatin treated CMN-1 and CCSK-BG 1 cells over a 20 hour period and
analyzed by western blot (Figure 8). CMN-l and CCSK-BGI blots probed with p53
monoclonal antibody (clone DO-7) demonstrated increased p53 protein expression (Figure
8A). W4 cells and W16 cells were included as a negative and positive control, respectively,
for p53 protein expression (Figure 8B). Increased p21 expression was noted in both CMN-l
and CCSK-BG 1 cells. p21 protein levels peaked between 6 an 10 hours in CMN-l cells and
between 2 and 6 hours in CCSK-BGI cells (Figure 8C).
Comparative quantification ofp53 mRNA and protein levels in CMN-l and CCSKBO 1 cells after exposure to cisplatin was also performed (Figure 9). In CMN-l cells, p53
protein levels increased over four times over a twenty hour period. In CCSK-BG 1 cells, p53
protein expression increased over eight times as compared to the control (untreated) sample.
Levels ofp53 mRNA steadily declined in both CMN-l and CCSK-BGI cells over twenty
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hours.

4. Flow Cytometric Evaluation of G 1 Cell Cycle Arrest
Flow cytometric cell cycle analysis using propidium iodide staining was included as
a final test to evaluate the ability of the p53 immunoreactive cell lines to arrest in G 1 or G2
phase of the cell cycle following DNA damage by cisplatin. CMN-l and CMN-2 cell lines
were evaluated for their ability to arrest in G 1 phase of the cell cycle after treatment with
cisplatin. CMN cells were compared to the p53 null anaplastic Wilms' tumor cell line W4.
Both CMN cultures exposed to cisplatin demonstrated G 1 arrest after four hours of cisplatin
exposure (Figures 10-12 and Table II). CMN-2 cells demonstrated a marked increase in the
percentage of cells at G 1 after 2 hours of exposure to cisplatin. CMN-1 cells, in contrast,
appeared to arrest more slowly. In contrast, the p53 null W4 cell line exhibited little to no
increase of cells in G 1 phase over the same time period.

5. Steady State mRNA Expression ofp53, p21, MDM-2, and MDR-l in CCSK and CMN
Primary Tumors.
The use of northern analysis was employed in the evaluation of the steady-state levels
of elements of the p53 cell signalling pathway. The presence ofp53 mRNA was used to rule
out deletion of this gene while steady-state p21levels suggests the normal functioning of the
p53 protein as well. Evaluation for MDR-J expression was included as a comparison to
Wilms' tumors as some anaplastic tumors overexpress this protein (Re et al., 1997).Total
cellular RNA was extracted from CCSK primary tumors and analyzed using northern analysis
(Figure 13). RNA was probed withp53, p21, MDM-2, MDR-1, and GAPD cDNA fragments
to evaluate the steady-state expression of these genes in CCSK primary tumor specimens. KB-
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VI, an epidermoid carcinoma cell line, was included as a positive control for amplification
of the MDR-l gene. SJSA-l pluripotential sarcoma cells were included as a control for
MDM-2 amplification. p53 and p21 mRNA levels were detected in all CCSK tumor
specimens examined. There was no evidence for gross gene rearrangement of p53 or MDM-2
overexpression in any CCSK case examined. There was also no evidence for MDR-l
amplification or overexpression in CCSK primary tumors. Hybridization with a GAPD cDNA
fragment was included as a marker for constitutive gene expression.
Northern analysis ofCMN primary tumors was also conducted using probes specific
for p53, p21, MDM-2, and GAPD (Figure 14). All primary tumors expressed detectable levels
of both p53 and p21 mRNA with no evidence of a gross p53 gene rearrangement or deletion.
MDM-2 expression was detected at low levels in 2 classical CMN cases. There were no
differences in gene expression between classical and cellular variants ofCMN.

97

III. Discussion
Mutations of the p53 tumor suppressor gene appears to constitute at least one
mechanism of tumor progression in the potentially aggressive and drug-resistant anaplastic
Wilms' tumor. In a study of 11 Wilms' tumors with anaplastic features, p53 mutations were
documented in 73% of cases (Bardeesy et al., 1994).Other reports have indicated p53
mutations in 66% of anaplastic tumors (EI-Bahtimi et al., 1996). Others have correlated p53
protein immunoreactivity with poor outcome in Wilms' tumor (Lahoti et al., 1996). A p53
mutation was also linked to overexpression of the MDR-J gene in an anaplastic Wilms' tumor
that led to patient death (Re et al., 1997). Because of the association ofp53 mutations with
pediatric renal tumors bearing poor prognosis, p53 protein expression was examined by
immunohistochemistry in a series of CCSK, another potentially aggressive childhood renal
tumor with a propensity for bone metastases (Cheah et al., 1996). This report indicated that
nuclear p53 protein was detectable in all eight cases examined leading to speculation that
there may be a common genetic mechanism leading to resistance and poor outcome in
pediatric renal tumors. This hypothesis was further bolstered a report of a translocation
(10;17) breakpoint involving chromosomel7pl3, the site of the p53 gene locus (Punnett et

al., 1989).
To begin to test such a hypothesis, we examined CCSK and CMN cell cultures,
primary tumors for p53 protein and mRNA expression using immunochemistry and northern
analysis, respectively. p53 nuclear accumulation is an established marker for p53 mutations
so cells which demonstrate immunoreactivity may harbor p53 mutations (Esrig et al.,
1993).Both CMN cell cultures and CCSK cell lines were initially evaluated for p53
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expression. Surprisingly, p53 nuclear reactivity was exhibited by cells derived from the
benign CMN and not in CCSK tumor cells. Subsequent SSCP and DNA sequencing failed
to demonstrate the presence of a p53 mutation in these immunoreactive cells. To eliminate
the possibility that p53 nuclear reactivity in CMN cells was not a characteristic only found in
cell cultures, a series of CCSK and CMN frozen and paraffin embedded tumors were
examined. This experiment did not show p53 nuclear reactivity in any of the tumor sections
examined. In the absence of p53 mutations, overexpression of the p53 binding protein and
oncoprotein MDM-2 constitutes an alternative means of p53 inactivation (Momand et al.,
1992). In addition, MDM-2 is amplified in many bone and soft tissue sarcomas leading to the
hypothesis that MDM-2 amplification or overexpression is a plausible occurrence in the
"sarcomatous" renal tumors of childhood. Furthermore, MDM-2 overexpression stabilized
p53 protein in rhabdomyosarcoma cell lines (Keleti et al., 1996). This led to the hypothesis
that MDM-2 may provide an explanation for the p53 nuclear reactivity in our CMN cultures.
N orthem analysis of both CMN and CCSK primary tumor tissue did not reveal any evidence
for MDM-2 amplification or overexpression, dismissing the role of this gene in CMN and
CCSK tumorigenesis. The lack ofMDM-2 overexpression in these tumors is consistent with
a previous report which identified MDM-2 amplification as a rare occurrence in pediatric
tumors (Waber et al., 1993).
In addition, CCSK tumors did not exhibit MDR-1 overexpression by northern analysis.
Lack of MDR-l expression in these tumors contrasts with that previously reported for an
epithelial-predominant anaplastic Wilms' tumor that led to patient death (Re et al., 1997).
These data also suggest that MDR-l overexpression is limited to cells with epithelial
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differentiation, that CCSK tumors are not comprised of epithelial cells, and that this gene is
not responsible for the potentially poor outcome in this tumor type.
Since

tumors

with

p53

mutations

are

not

always

detected

USIng

immunohistochemistry, we subjected both CMN and CCSK cell cultures to the DNA
damaging chemotherapeutic drug cisplatin to test the ability of the p53 protein to transactivate
its downstream effector genes p21, MDM-2 and Bax .This is a technique which has been used
successfully in many cell types to evaluate p53 functional capabilities (O'Connor et al., 1997).
Both of the CMN and CCSK cell lines exposed to cisplatin demonstrated p21 induction with
varying kinetics over 8 hours of exposure. In contrast, anaplastic Wilms' tumor cells with p53
mutations demonstrated a diminished to absent induction of p21. Flow cytometric cell cycle
evaluation revealed G 1 cell cycle arrest in all CMN and CCSK cell cultures, but not in p53
null W4 anaplastic Wilms' tumor cells, demonstrating the ability of the p53 protein to mediate
a signal transduction cascade, through p21 ,leading to cell growth arrest. Furthermore, the proapoptotic Bax gene was induced in both CMN-1 and CCSK-2 cells over 20 hours. Bax mRNA
levels declined, however, in CCSK-BG 1 cells. MDM-2 gene expression was also induced in
CMN and CCSK cell lines with varying kinetics. p53 mRNA levels was not affected in any
of the cisplatin treated cell lines indicating that p53 protein mobilization and not p53 mRNA
induction is important in the cellular response to DNA damage. Previous reports have
indicated that wild-type p53 protein induction occurs during the cellular response to DNA
damage (Kastan et al., 1991). Therefore, CMN-l and CCSK-BG1 cells were exposed to
cisplatin for intervals of two hours for a total of twenty hours. Both cell cultures exhibited
protein stabilization over this time period consistent with the normal function ofp53.
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Taken together, these data indicate that p53 mutations are not present in CCSK and
CMN tumors, a finding that contrasts the p53 genotype in anaplastic Wilms' tumor cells. An
explanation for the p53 nuclear reactivity in CMN cells is not known. However, the p53
protein may be rendered more stable in cell culture conditions for these cell types.
Alternatively, p53 may be stabilized by other p53 binding proteins such as 53BP2 (Gorina et
aI., 1996). Previous studies have suggested that inactivation of p53 enhances the sensitivity

of some cells to chemotherapeutic agents (Hawkins et al., 1996). For example, the p53 null
W4 anaplastic Wilms' tumor cells, derived from a patient that died from disease, were more
sensitive to cisplatin exposure than the CMN-l cell line which was derived from a benign
tumor with a normal p53 gene. Therefore, this study also demonstrates the utility of evaluating
the function ofp53 in pediatric renal tumor cells and has implications for the uses of DNA
damaging agents as a chemotherapeutic treatment strategy in these tumors.
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Figure 1. Immunocytochemical evaluation of p53 protein in cultured CCSK and CMN cells.

Column A, Cells stained with mouse monoclonal antibody to p53 (clone DO-7) and
rhoadamine-conjugated secondary goat anti-mouse antibody. Column B, corresponding phase
micrograph to Column A. Column C, cells which received only secondary rhodamineconjugated goat anti-mouse antibody. Column D, corresponding phase micrographs to
Column C. Rows indicate cell line evaluated. OVCAR (ovarian carcinoma) cells and
anaplastic Wilms' tumor cells bear p53 mutations and act as controls for the p53 protein.
Anaplastic W4 cells contain no immunochemically detectable p53 protein.
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Figure 2. Northern analysis ofp21, p53, and GAPD in cisplatin treated CCSK and CMN cell
cultures. Cell lines employed in experiment are indicated at top of blot. The different genes
analyzed are noted at the left of each blot. Cisplatin exposure times are indicated above each
lane in hours (0 hours = untreated cells). A, Induction ofp21 mRNA over 8 hours of cisplatin
exposure. CMN-1, CMN-2, CCSK-2 and CCSK-BG 1 induced p21 mRNA in varying degrees.
W 4 and W16 anaplastic Wilms' tumor cells bearing p53 mutations were included as negative
controls. B, Evaluation ofp53 mRNA over 8 hours of cisplatin exposure. C, Hybridization
with a GAPD cDNA fragment was included as a control for constitutive gene expression.
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Figure 3. Northern analysis ofp53, p21, MDM-2, Bax, Bcl-xL and GAPD mRNA in CCSK
and CMN cell cultures exposed to cisplatin. Cells employed in experiments are indicated
above each blot. Genes analyzed are noted at the left of each blot. Cisplatin exposure times
are noted above each lane. A, Northern analysis of p53, p21, MDM-2, Bax, and GAPD.
Hybridization with a GAPD cDNA probe was included to ensure for equal lane loading in
both A and B. W4 cells are included as a negative control for p53. C, Northern analysis of
Bcl-xL in CMN-l and CCSK-2 treated for 20 hours with cisplatin.
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Figure 4. Line Graph illustrating p21 waf-l mRNA quantification over twenty hours of

exposure to cisplatin in CMN-l, CCSK-2, and CCSK-BGI cell cultures. A key to the right
of the graph identifies the cell types used in the experiment. mRNA quantification was
performed using Adobe Photoshop version 4.0 Software.
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Figure 5. Line graph illustrating p53 mRNA quantification over twenty hours of exposure to
cisplatin in CMN-l, CCSK-2, and CCSK-BGI cell cultures. A key to the right of the graph
identifies the cell types used in the experiment. mRNA quantification was performed using
Adobe Photoshop Version 4.0 software.
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Figure 6. Line graph illustrating MDM-2 mRNA quantification over twenty hours of
exposure to cisplatin in CMN-1, CCSK-2, and CCSK-BG 1 cell cultures. A key to the right
of the graph identifies the

c~ll

lines used in the experiment. mRNA quantification was

performed using Adobe Photoshop Version 4.0 software.
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Figure 7. Line graph illustrating quantification ofBax and Bcl-X mRNA over twenty hours
of exposure to cisplatin. A, Bax and Bcl-X mRNA quantification in CMN-I cells. B, Bax and
Bcl-X quantification in CCSK~2 cells. Quantification was performed using Adobe Photoshop
Version 4.0 software.
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Figure 8. Western blot analysis ofp53 and p21 protein in CMN-I and CCSK-BGI cells after
20 hours of exposure to cisplatin. Exposure time is noted above each lane and cells used are
indicated at the left of each blot. A, Western analysis ofp53 using the mouse monoclonal p53
antibody (clone DO-7) showing p53 accumulation over 20 hours in both CMN-I and CCSKBG 1. B, p53 negative and positive controls. p53 mutant W4 cell extracts lack demonstrable
p53 protein. p53 mutant WI6 cell line, in contrast, shows abundant p53 protein. C, Western
analysis of p2I using a mouse monoclonal antibody in cisplatin exposed CMN-1 and CCSKBO 1 cells. p21 protein levels increased over 10 hours in CMN-l cells. In contrast, p21 protein
levels rose between 2 and 6 hours in CCSK-BGI cells before declining at 8 hours. Equal
amounts of protein were loaded into each lane.
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Figure 9. Comparative Quantificationofp53 mRNA and protein in CMN-l and CCSK-BGI
cell cultures. A, Quantification of p53 mRNA and protein over twenty hours of cisplatin
exposure in CMN-1 cells. B, Quantification of p53 mRNA and protein over twenty hours of
cisplatin exposure in CCSK-BG 1 cells. Quantification was performed using Adobe Photoshop
Version 4.0 software.

450

400

350

A.

300
p53 protein

e'E

250

0

u

'0
~

200

150

100
p53 mRNA

50

0
0

2

20

10

8

6

4

cisplatln exposure time, hours

900

800

B.

700

600

'0
... 500

'E
0

u

'0
";!.

400

300

200

100

p53 mRNA

0
0

2

4

6

8

clsplatln exposure time, hours

10

20

119

Figure 10. Flow cytometric cell cycle analysis of CMN-1 cells exposed to cisplatin over four
hours. Relative DNA content and cell number represent the x- and y- axes, respectively.
Percentage of cells in each phCl:se of the cell cycle are noted at the right of each histogram. A,
Control, CMN-l cells receiving no cisplatin. B, CMN-l cells treated for two hours with
cisplatin. C, CMN-l cells treated for four hours with cisplatin.
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Figure 11. Flow cytometric cell cycle analysis ofCMN-2 cells exposed to cisplatin over four
hours. Relative DNA content and cell number represent the x- and y- axes, respectively.
Percentage of cells in each phase of the cell cycle are noted at the right of each histogram. A,
Control, CMN-2 cells receiving no cisplatin. B, CMN-2 cells treated for two hours with
cisplatin. C, CMN-2 cells treated for four hours with cisplatin.
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Figure 12. Flow cytometric cell cycle analysis of the p53 null, anaplastic Wilms' tumor W4
cells exposed to cisplatin over four hours. Relative DNA content and cell number represent
the x- and y- axes, respectively. Percentage of cells in each phase of the cell cycle are noted
at the right of each histogram. A, Control, W4 cells receiving no cisplatin. B, W4 cells treated
for two hours with cisplatin. C, W4 cells treated for four hours with cisplatin.
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Figure 13. Northern analysis ofp53, p21, MDM-2, MDR-1, and GAPD mRNA in CCSK
primary tumor specimens. Tumor sample identity is noted above each lane. Genes evaluated
are noted at the left of each blot.An ethidium bromide stained gel is included to document
RNA integrity. KB-V 1 is a epidermoid carcinoma cell line known to contain amplified copies
of the multi drug resistance gene, MDR-l. SJSA-l is a pluripotential sarcoma cell line with
documented MDM-2 amplification. The presence ofp53 and p21 mRNA is noted in all CCSK
examples with no evidence of gene rearrangement. CC-50013 (lane 3) contains a degraded
RNA sample and is non-informative. There is no evidence of MDM-2 or MDR-l
amplification or overexpression in any CCSK sample evaluated. Hybridization with a eDNA
probe specific for GAPD was included to ensure for gel loading efficiency.
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Figure14. Northern analysis ofpS3, p21, MDM-2 and GAPD in cellular (ce) and classical (cl)
CMN primary tumor specimens. Tumor specimen identity is noted above each lane. Genes
evaluated are listed to the left of each blot. An ethidium bromide gel is included at the bottom
to document the integrity of each RNA sample. SJSA-l mRNA was derived from a
pluripotential sarcoma with documented MDM-2 amplification. Both cellular and classical
CMN contain pS3 and p21 mRNA with no evidence of gene rearrangement. There is no
evidence ofMDM-2 amplification or overexpression in CMN primary tumors. Hybridization
with a GAPD cDNA probe was included to ensure for gel loading efficiency.
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Table lA. Immunohistochemical Results on Frozen CCSK Primary Tumor Specimens
Stain ed with p53 monoclonal antibody (DO-Tl
Tumor Specimen
Case ID

Tumor Stage

p53
Immunoreactivity

CC-209

Stage I

-

CC-236

Stage II

-

CC-462

Stage III

-

CC-50057

Stage unknown

-

CC-50113

Stage II

-

ceCMN-357

Stage I

-

c1CMN-458

Stage I

c1CMN-482

Stage II

-

ceCMN50044

Stage I

-

ceCMN50524

Stage I

-

esophageal squamous cell
carcinoma

Stage unknown

+++

Table lB. Summary ofp53 Immunohistochemical and Gene Structure Data for CCSK
and CMN C eII C u Itures, P arafftIn E m b edd ed P rlmary
·
T umor, an d Xenograft T·ssue
1
p53
immunochemistry
cells

p53
im m unochemistry
paraffin

p53 gene structure

CCSK-I

+/-

-

NID

CCSK-2

-

-

wild-type

CCSK-3

-

-

NID

CCSK-BG1

-

-

N/D

CMN-I

++

-

wild-type

CMN-2

++

+/-

wild-type

W4 anaplastic

-

-

point mutant

W16 anaplastic

++++

++++

point mutant

Cell Culture
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Table II. Flow Cytometric Cell Cycle Analysis of Cisplatin Treated CMN and
Anaplastic Wilms' Tumor Cells (Gl = Gl pbase ortbe cell cycle)

Cell Line

p53
1m m unoreactivity

% cells in

p53
gene
status

Gl
untreated

% cells in
Gl

2 hours

% cells in
Gl
4

hours

CMN-l

positive

wild-type

59.7

64.5

72.0

CMN-2

positive

wild-type

55.4

84.8

85.3

W 4(anaplastic)

negative

mutant

24.4

25.8

26.0

Chapter 5
Steady State and Retinoic Acid Induced Gene Expression Analysis of Clear Cell
Sarcoma of the Kidney and Congenital Mesoblastic Nephroma: A Model
For Tumor Histogenesis

I. Introduction
Pediatric renal tumors represent one of the most common abdominal tumors affecting
young children and have long been interpreted as aberrations of normal nephrogenesis
(Gonzalez-Crussi, 1984). These neoplasms may be subclassified based upon their clinical
behavior, their association with genetic syndromes, cytogenetic lesions, and distinctive
histological characteristics (Murphy et al., 1994). By far the most common childhood renal
tumor, Wilms' tumor, or nephroblastoma, is most readily recognized as a developmental
anomaly. These tumors are often characterized by their classical, triphasic histology which
includes disorganized, immature tubular elements, blastema, and stromal tissue, or different
combinations of the three latter cell types, structures which are also evident in the developing
fetal kidney. Because of the close parallel in the cellular architecture between Wilms' tumor
and fetal kidney tissue, it has been suggested that tumorigenic events probably occur during
key points in the development of the kidney (Re et al., 1994). In contrast to the relatively
straightforward interpretation of Wilms ' tumor histogenesis, the origins of other renal tumors
of childhood are more subtle. One example is clear cell sarcoma of the kidney (CCSK) which
was first delineated from Wilms' tumor in several reports dating to the 1970s (Kidd,

1970~

Beckwith et al., 1978). CCSK, which accounts for approximately 5% of all renal tumors of
children, has Wilms' tumor distinguishing clinicopathologic features including a delicate
chromatin pattern creating empty-appearing nuclei, prominent hyalinization, and a propensity
for the development of bone metastases, a characteristic which sharply contrasts the usual
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favorable outcome of most Wilms' tumors (Murphy et al., 1994). Although the histogenetic
origin of this tumor is unknown, some have suggested that it may arise from renal medullary
interstitial, mesangial, endothelial, or blastemal cap cells (Beckwith et al., 1978; Haas et al.,
1984). Authors of these same reports also speculated that CCSK may represent the malignant
counterpart of the relatively benign, congenital mesoblastic nephroma (CMN) (Beckwith et
al., 1978). Compared to CCSK, CMN is a relatively benigntumor first described by Bolande

which primarily affects neonates as the vast majority of cases are diagnosed in the first three
months of life (Bolande et al., 1967; Wigger, 1969). Like CCSK, CMN accounts for 5% of
all childhood renal malignancies and is the most common abdominal tumor of neonates.
CMNs may be further subdivided into two categories based upon their histology and clinical
behavior: the classical and the more common and potentially more aggressive cellular CMN
(Murphy et al., 1994; Joshi et al., 1986). Like CCSK, the developmental origin of CMN is
unresolved even though its histological appearance suggests that it is a neoplasm of
fibroblasts or myofibroblasts (Parham, 1996). Hypotheses regarding the histogenesis of both
CMN and CCSK are primarily based upon electron microscopic studies and
immunohistochemistry (Haas et al., 1984; Kumar et al., 1986; Pettinato et al., 1989). To date,
the gene expression profile of CMN and CCSK have not been completely evaluated in the
context of the genetic basis of normal kidney development.
The development of the metanephros, or functioning adult kidney, occurs via
reciprocal inductive events between the metanephric mesenchyme and the ureteric bud
(Saxen, 1987). As development proceeds, metanephric mesenchyme differentiates into most
structures of the nephron including the glomerulus and tubules. The ureteric bud, instead,
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forms elements of the renal collecting duct system and the Columns of Bertin. With the
introduction of molecular biological techniques, a large and varied array of genes which
control normal kidney development have been identified (Lechner et al., 1997).
WT -1 is a well recognized example. WT-1 is a zinc finger tumor suppressor gene that
is deleted or mutated in Wilms' tumors and responsible for proper formation of the
urogenital system (Call et al., 1990; Kreidberg et al., 1993). WT-1 expression is induced in
metanephric mesenchyme following ureteric bud induction an remains expressed at high
levels throughout the comma-shaped and S-shape stages of nephron formation. In the adult,
WT-1 is only expressed in glomerular podocytes. WT -1 expression is also highly expressed
in many Wilms' tumors, particularly in areas of blastema and tubular differentiation
suggesting that Wilms' tumors are derived from areas of induced, condensing renal
mesenchymal tissue (Pritchard-Jones et al., 1991). Two previous reports demonstrated the
absence ofWT-1 transcripts in two cases each ofCCSK and CMN (Yun, 1993; Tomlison
et aI., 1992).

The WT -1 transcription factor mediates the expression of several key genes involved
in fetal tissue growth and pediatric neoplasia including IGF-2. IGF-2 is overexpressed in
many pediatric tumor types (Reeve et al., 1985). Interference of IGF-2 binding with its
cognate receptor, IGF-1R, by the use of a monoclonal antibody specific for the receptor
inhibits the growth of Wilms' tumors in vitro and in vivo (Gansler et aI., 1989). The latter
suggests the importance of an IGF-2 autocrine growth loop in Wilms' tumor cell
proliferation. Detection of an IGF -2 binding protein, BP-2, has also been described in
Wilms' tumor cells, although the modulatory role that this protein plays in Wilms'
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tumorigenesis or its role in IGF-2 mediated autocrine growth is unresolved (Vincent et al.,
1994). In other cell systems, BP2 has been reported to both inhibit and potentiate cell growth
depending upon the cell system employed (Jones et aI., 1995).
Pax-2 and Pax-8 are both paired box class transcription factors that are expressed in
two partially overlapping, asynchronous waves during nephrogenesis. Pax-2, like WT-1, is
induced following ureteric bud induction and persists throughout the early stages of
nephrogenesis (Dressler et al., 1990). In contrast, Pax-8 is expressed at a later stage, as it
remains expressed in the S-shaped body (Poleev et al., 1992). Like WT-1, expression of Pax2 an Pax-8 is a marker of induced metanephric mesenchyme; cells of the stromal lineage,
presumably cells not receiving inductive signals, do not express WT-1, Pax-2, or Pax-So The
expression pattern of the normal kidney closely parallels findings in Wilms' tumor. WT-l,
Pax-2, and Pax-S are expressed in both blastema and areas of tubular differentiation in
Wilms tumors, but not in stromal areas, as assessed by in situ hybridization (Eccles et al.,
1995).
WT-1, Pax-2, and Pax-8 are all markers for renal tubules and the non-vascular
glomerulus of the developing nephron. Very few markers have been identified for the
developing renal stroma, or interstitium (Ekblom et al., 1991). Tenascin, a mesenchymal
extracellular matrix protein, is expressed in areas of dense mesenchymal tissue immediately
surrounding differentiating epithelium, a pattern which is consistent with that this protein is
critical for normal mesenchymal to epithelial transformations in several developing organs,
including the kidney (Chiquet-Ehrismann et al., 1986). Tenascin expression was absent from
the uninduced mesenchyme and cells undergoing epithelial differentiation in developing
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mouse kidney (Aufderheide et al., 1987). The latter study also reported persistence of
tenascin expression in the medullary renal interstitial areas with loss of expression in renal
cortical areas after nephrogenesis ceased. Others have demonstrated that tenascin
immunoreactivity is also detectable in the glomerular mesangium with increased amounts
noted in glomerulopathies and interstitial nephritides (Koukoulis et al., 1991). Therefore,
these data suggest that tenascin may provide one of the few known markers for a better
understanding of pediatric renal tumor histogenesis, particularly those with hypothesized
stromal origins.
The newly described marker of renal stroma, the winged-helix transcription factor BF -2, will
also aid in the evaluation of both normal stromal development and the formation of pediatric
renal tumors (Hatini et al., 1996).
The use of differentiation agents such as all-trans retinoic acid (atRA) has been useful
in understanding the pathobiology and histogenesis of a variety of tumor types including
neuroblastoma and promyelocytic leukemia (Wada et al., 1992; Brietman et al., 1980). AtRA
induces differentiation in cells by binding to nuclear Retinoic Acid Receptors (RAR) which
are capable of homo- and heterodimerization with retinoid X-receptors. Among the effects
of atRA on gene expression, is its potent induction of several RAR isoforms including RAR-

a during differentiation (Leroy et al' 1991) Subsequently, these receptors bind to retinoic
J

acid response elements (RARE) in target genes (Leid et al., 1992). Among other genes,
expression of cell cycle regulatory genes p53 and p21 are also affected upon atRA treatment
(Dony et al., 1985; Liu et al., 1996).Because Vitamin A derivatives including atRA have
previously described utility in inducing differentiation in metanephros organ culture (Vilar
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et al., 1996) and in other pediatric tumors including neuroblastoma, this differentiation agent

was chosen to test the hypothesis that CCSK, CMN, and Wilms' tumors are each derived
from precursor cells at different renal developmental stages.
In this report, we have evaluated the expression profile ofWT-l, Pax-2, Pax-8, IGF2, BP-2, and tenascin using northern analysis in a series of CCSK and CMN primary tumors
as a means of beginning to understand the histogenesis of these neoplasms in relation to
Wilms' tumor. Furthermore, we have treated CCSK and CMN cell cultures with all-trans
retinoic acid, evaluated changes in gene expression, and correlated these changes with
morphological alterations assessed by transmission and electron microscopy.
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II. Results
1. Expression of Genes Involved in Normal Nephrogenesis in CCSK and CMN Primary
Tumors
A series ofCCSK (Figure 1) and CMN (Figure 2) primary tumors was examined for
tenascin, WT-I, Pax-2, Pax-8, IGF-2, and BP-2 gene expression using northern analysis.
Tenascin was expressed at low levels in 3/7 CCSK tumors. In contrast, tenascin mRNA was
expressed at high levels in both cellular and classical CMN tumors. Tenascin expression was
undetectable in an epithelial anaplastic Wilms' tumor (WI7) (Figure 2) and in the KB-VI
epidermoid carcinoma cell line. Tenascin was expressed in a triphasic classical Wilms'
tumor WI 1 (Figure 1). SJSA-I pluripotential sarcoma cells were included as an independent
comparison in both panels and expressed low levels of tenascin mRNA (Figure 1&2).
Expression ofWT -1 was absent in 100% of all CCSK primary tumors examined. In contrast,
WT-I mRNA was detectable in 3/6 CMN tumors (1 classical and 2 cellular tumors). Both
WI 1 and WI7 tumors expressed WT-I message. Pax-2 was variably expressed in 3/7 of
CCSK and 1/3 ofCMN tumors examined. Both Wilms' tumors WI 1 and WI7 were included
as positive controls for Pax-2 expression. Pax-8 mRNA was detected in one CCSK and two
CMN tumors. IGF-2 and BP-2 were highly expressed in CCSK, CMN, and WT examined
with rare exception. Hybridization with a GAPD cDNA probe was included as an indicator
of constitutive gene expression.

2. Phase Contrast Microscopy of atRA Treated CCSK and CMN Tumor Cells
To attempt to understand the cellular origin for these rare renal neoplasms of
childhood, cultured tumor cells were treated with the morphogen atRA for three days in a
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dark incubator. Figure 3 illustrates the light microscopic characteristics of CCSK-2 and
CCSK-BGI tumor cell cultures treated with 1

~M

atRA. Both untreated cell cultures

demonstrated round to spindle shaped morphology. atRA treated cell cultures exhibited focal
areas of close cellular clumping, in some instances forming mounds (Figure 3D). CCSK-2
cultures also formed clusters of closely juxtaposed cells. Untreated CCSK-2 and CCSK-BG 1
cell cultures were also noted to contain foci of closely opposed cells upon re-examination,
however, indicating that the light microscopic features of these cells were not due to atRA
exposure alone.
Concurrent experiments treated SK-N -SH neuroblastoma cells and both CMN-1 and
CMN-2 cells with 1 f..lM atRA (Figure 4). SK-N-SH cells exhibited the formation of
interlacing neurite structures after 72 hours of atRA treatment indicating that neuroblastoma
cells were induced to differentiate. In contrast, there was no light microscopic indication of
cellular differentiation in either of the CMN cell cultures examined. Both cell cultures
maintained a rounded spindle shaped morphology during the experiment. CMN-2 cells
continued to grow in the presence of atRA as indicated by their increased cellular confluency.

3. TEM and SEM Analysis of atRA Treated CCSK and CMN Cell Cultures
The same atRA treated cell cultures ofCCSK-2 and CMN-I photographed using
phase contrast microscopy were fixed for TEM and SEM analysis. Untreated CCSK-2 cells
demonstrated cells growing in multipile layers by TEM (Figure SA) whereas those cells
exposed to atRA for three days exhibited marked cellular interdigitation (Figure 5B).There
was no apparent signs of intracytoplasmic organellar composition or development of
intracellular filaments in treated versus untreated tumor cells. Furthermore, indications of
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epithelial differentiation including the development of cell polarity was not found To better
visualize the three dimensional affects of atRA on morphology, CCSK-2 tumor cells were
examined using SEM. Whereas the untreated cells demonstrated cells with a dome-shaped
morphology intermixed with flatter cells, atRA exposed cells were tightly opposed and
flattened (Figure 5 C&D).
CMN-l cells treated with atRA exhibited marked cellular changes by TEM and SEM
analysis that were not apparent using phase microscopy alone (Figure 6). CMN-l cells that
were not treated with atRA grew in sheets of cells that were not closely juxtaposed. Upon
three days exposure to atRA, CMN-l cells became closely interdigitated and flattened
leaving little intercellular space (Figure 6 B&D). As in CCSK-2 cells, there was no evidence
of intracellular organellar change or development of intermediate filaments in CMN-1 cells.

4. atRA Induced Gene Expression Alterations in CCSK and CMN Cells
Total cellular RNA was extracted from CMN-l, CMN-2, CCSK-2, CCSK-BGl, and
SK-N-SH neuroblastoma atRA treated cell lines were evaluated for alterations in mRNA
expression for genes that are important for normal nephrogenesis using northern analysis
(Figures 7-10). atRA exposed CCSK-2, but not CCSK-BG 1 cells exhibited induction of both
tenascin and Pax-2 mRNA over a 48 hour time period. W17 and W16 anaplastic Wilms'
tumor cells were included as a positive control for Pax-2 mRNA. IGF-2 mRNA levels
initially increased in SK-N-SH neuroblastoma cells before declining at 72 hours. Neither
CCSK-2 nor CCSK-BG 1 cells revealed IGF-2 mRNA differences over 48 and 72 hours of
atRA exposure, respectively. RAR-a gene expression was induced in SK-N-SH
neuroblastoma cells over 48 hours before declining at 72 hours. CCSK-2 cells demonstrated
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no significant RAR-a induction over 48 hours. In contrast, CCSK-BG 1 cells revealed
induction of the 3.5 kb RAR-a transcript over 72 hours with a concomitant decrease in a
transcript migrating at 2.3 kb. There was no apparent change in p53 gene expression in any
of the atRA treated cell cultures. Furthermore, there was no significant changes in p21
expression in either CCSK-2 or CCSK-BG 1 cells, but a significant increase was noted in SKN-SH cells at 48 hours of atRA exposure.
CMN-l, but not CMN-2 cells treated with atRA exhibited several gene expression
alterations over 72 hours. In contrast to CCSK-2 cells, tenascin mRNA decreased in CMN-l
cells with a concurrent induction ofPax-2 mRNA (Figures 9-10). IGF-2 and BP-2 mRNA
levels remained stable in CMN-l cells through 48 hours before declining at 72 hours. RAR-a
mRNA was induced in the first 48 hours in CMN-l cells before declining at 72 hours.
Similar to the findings in CCSK cell cultures, both CMN cultures did not reveal any changes
in p53 gene expression. p21 message, in contrast, was induced in SK-N-SH and declined at
72 hours in CMN-l cells. Hybridization of RNA to a GAPD cDNA fragment was included
as a control for constitutive gene expression. A model for the histogenetic origin of Wilms'
tumor, CMN, and CCSK is presented in Table 11. This model is based on the steady-state
and atRA induced gene expression profile of genes expressed during normal nephrogenesis.
The hypothesized origins for these tumors are noted.
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III. Discussion
Current understanding of the histogenesis of pediatric renal tumors has been largely
based upon light and electron microscopy and immunohistochemical studies (Haas et al.,
1984; Kumar et al., 1986; Pettinato et al., 1989). These reports have supported the distinction
ofCCSK and CMN from Wilms' tumors and other childhood renal tumors. However, studies
have not evaluated a sufficient number of cases to be meaningful due to the relative rarity of
both neoplasms. Furthermore, the study of the cellular origin of these tumors has been
hindered by the lack of an experimental model to test current CCSK and CMN histogenetic
hypotheses. In the present study, we were able to evaluate a large series ofCCSK and CMN
primary tumors for mRNA expression of genes controlling the normal nephrogenic program,
such as WT-l Pax-2, and tenascin, in an effort to build a working model of the
developmental origin of these neoplasms. Furthermore, both tumors were evaluated for
morphological and gene expression alterations after treatment with the morphogen atRA in
an in vitro differentiation assay.
Previous molecular biological analysis of CCSK and CMN has been limited. Two
independent studies reported that CCSK and CMN expressed the fetal mitogen IGF-2 and
not the Wilms' tumor suppressor gene, WT-l (Yun, 1993; Tomlison et al., 1992). In the
present study, WT-1 was not expressed in 7 CCSK primary tumors examined, although WT 1 message was detected in three CMN tumors. In addition, WT-1 expression was previously
detected in two CMN nude mouse xenografts. The latter represents the first reported
expression ofWT-1 in this tumor type. Unlike WT-l, IGF-2 and the IGF-2 binding protein
BP-2 were highly expressed in both CCSK and CMN supporting an embryological origin of
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these tumors. Further analysis ofCCSK and CMN primary tumors revealed Pax-2 expression
in selected tumor specimens. The latter contrasts with previous reports of one CCSK and one
CMN which indicated no expression ofPax-2 or Pax-8 and other reports which demonstrated
Pax-2 and Pax-8 expression in Wilms' tumors and in induced mesenchyme (Tagge et al.,
1994; Dressler et al., 1992; Poleev et al., 1992). The observation of both WT-l and Pax-2
mRNA in some CMN and Pax-2 mRNA in selected CCSK has two alternative explanations.
Firstly, the presence of Pax-2 mRNA may be explained by entrapped normal kidney
glomeruli embedded within tumor tissue (glomerular podocytes express WT -1 postnatally).
However, this explanation does not explain WT-l expression in cellular CMN xenografts
analyzed previously since normal kidney tissue does not grow in nude mice. Alternatively,
this data may indicate that CMN tumors are derived from mesenchymal cells in close
juxtaposition with the condensing mesenchyme that receive inductive signals from the
ureteric bud. Pax-2 expression in CCSK may be further indicative of the pluripotential nature
ofCCSK cells (i.e. their ability to differentiate into cells oftubulogenic potential). Previous
histological analysis of the three Pax-2 mRNA positive CCSK did not demonstrate evidence
of epithelial differentiation, however.
To clarify these results, CCSK and CMN were analyzed for tenascin mRNA
expression, a marker of cells surrounding the condensing renal mesenchyme and interstitial
cells (Ekblom et al., 1991; Aufderheide et aI., 1987; Truong et al., 1996). Tenascin
expression was extremely high in all CMN tumors examined and contrasted with the variable
and low tenascin mRNA content of CCSK. These data provides molecular evidence for the
origin of CMN in the uninduced renal mesenchymal tissue that is destined to become the
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interstitium of the kidney. Expression of tenascin in some CCSK further suggests the
possibility of its differentiation along multipile differentiation pathways including the
stromal lineage. The absence of WT-1, Pax-2, and tenascin expression in the majority of
CCSK cases also supports the notion that this tumor arises in primitive, uncondensed renal
mesenchyme.
atRA is a well characterized inducer of neural cell differentiation in neuroblastoma
cells (Robson et al., 1985) Due to this previously described utility of atRA, CCSK and CMN
cell cultures were treated with the differentiation agent atRA to evaluate morphological and
gene expression alteration.SK-N-SH neuroblastoma cells exhibited the characteristic
formation of neurites by light microscopy in atRA exposed cells. However, phase
microscopic analysis ofCCSK and CMN failed to demonstrate specific changes in cultures
that received retinoic acid similar to previous reports of an atRA treated Wilms' tumor
(Vincent et al., 1996). Both treated and untreated CCSK cultures, however, exhibited focal
areas of close cellular opposition and cell clumping interspersed with flat stromal cells
consistent with multipotential differentiation ofCCSK. CMN cells, in contrast, did not reveal
any light microscopic evidence of epithelial differentiation. However, TEM and SEM
analysis of both cell types treated with retinoic acid demonstrated marked changes in cellular
arrangement without any effect on intracytoplasmic ultrastructural features. Both CCSK and
CMN cultures exhibited marked cellular flattening and close cell juxtaposition in samples
treated for three days with atRA. The latter cultures provided no evidence of epithelial
differentiation in either tumor type as cell polarity, tight junctions, and rounded morphology
were not identified. These results, then, are consistent with fibroblastic or smooth muscle
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differentiation of CMN and CCSK. Previous studies in this laboratory identified smooth
muscle actin positivity in both the CCSK-2 and CMN-l cultures used in this experiment.
Future studies will include evaluating atRA induced changes in intermediate filament
composition in these cells in order to further characterize the effects of this differentiation
agent.
Cells which were evaluated morphologically were also evaluated for changes in gene
expression after exposure to atRA. Gene expression alterations varied within and between
the cell types, but included induction oftenascin and Pax-2 in CCSK-2 cells. In contrast,
CMN-l cells exhibited downregulation oftenascin mRNA with a concurrent induction of
Pax-2 message. Tenascin induction in CCSK-2 cells provides further evidence for the origin
of this tumor in the uninduced renal mesenchyme as atRA may have spurred these cells to
differentiate into the interstitial lineage. The TEM and SEM and northern analysis data of
CCSK-2 supports this hypothesis. In contrast to CCSK, CMN-l cells exhibited
downregulation of tenascin in their differentiated phenotype. atRA has been previously
reported to induce tenascin expression in neuroblastoma cells and is consistent with our
findings in CCSK-2, but not CMN-l cells (Linnala et al., 1997). Pax-2 induction in CCSK-2
and CMN-1 cells also suggests the origin of these tumors in the uninduced mesenchyme. In
contrast to CCSK-2 and CMN-l, CCSK-BGI and CMN-2 cells do not exhibit gene
expression alterations after atRA exposure. The latter further illustrates the heterogenous and
pluripotential characteristics of these tumors.
atRA has also been reported to modulate the expression of IGF-2 and BP-2 in
neuroblastoma cell lines (Babajko et al., 1996). For that reason, these genes were evaluated
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for changes in our CCSK and CMN cells. No changes in IGF -2 mRNA levels were evident
in CCSK cells. However, CMN-l cells exhibited a downregulation of1GF-2 after 72 hours
of treatment. In contrast, SK-N-SH cells included in this experiment induced IGF-2 mRNA
at 48 hours supporting a previous report suggesting that IGF -2 induction is necessary for SKN-SH neuronal differentiation (Ueno et al., 1993). The lack oflGF -2 induction in CCSK and
CMN cells of this study discounts the role of increased IGF-2 in the differentiation of these
tumor cells. Downregulation of this gene in CMN-l at 72 hours suggests a resting cellular
phenotype that does not require IGF-2 expression. Further, the concurrent downregulation
ofBP-2 in CMN-1 cells lends support to the notion that BP-2 and IGF-2 function in tandem
in these cells and that both are not needed, or are only required at low levels, to maintain the
differentiated phenotype of these cells. This data does not discount the possible role of1GF-2
in the process leading to differentiation, however.
Finally, alterations in the expression of modulators of the cell cycle were also
evaluated in these tumors. Previous reports have indicated that the cyclin-dependent kinase
inhibitor, p21 is induced by retinoic acid exposure in hematopoietic and hepatoma cell lines
and that this modulation of expression was mediated through RAR-a (Steinman et al., 1994;
Liu et al., 1996). In our studies, p21 mRNA was not induced by atRA treatment in CCSK
and CMN cells. However, p21 was induced in our control SK-N-SH cell line. In addition,
the steady state level of p53 mRNA remained unchanged in CCSK and CMN cells.
Uniquely,p21 mRNA declined at 72 hours in CMN-l cells, possibly indicative of a resting
cellular phenotype. Therefore, upregulation of the p21 and p53 gene in CCSK and CMN cells
does not appear to be a requirement for differentiation. Again, this data does not rule out the
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possibility of post-transcriptional or post-translational mechanisms leading to increased p53
or p21 stability as a means of atRA mediated differentiation of these tumor cells.
In summary, atRA treatment ofCCSK and CMN cells caused dramatic morphological
changes in both. These changes did not, however, demonstrate overt signs of epithelial
differentiation in either tumor type. The distinct cellular flattening and close opposition of
cells is more consistent with fibroblastic or smooth muscle cell differentiation. Gene
expression alterations were variable in our tumor cell cultures, however, the changes noted
may have implications for investigating the histogenesis and retinoic acid -mediated control
of gene expression in these rare renal tumors of childhood in the future. Additionally, steadystate examination of gene expression for Pax-2, WT -1, and tenascin strongly suggest that
CMN cells arise from secondary mesenchyme destined to become the renal interstitium due
their high expression oftenascin mRNA. In contrast, our data suggests that CCSK cells are
derived from more primitive, pluripotent loose mesenchymal tissue. Some may argue that
CCSK and CMN arise from cells that have already been induced and lost certain gene
expression characteristics (such as WT -1 expression) linked to the condensing mesenchymal
phenotype. Previous studies using retroviral markers dismiss this notion, however In studies
of the embryological rat kidney, induced mesenchymal cells differentiated into proximal and
distal tubular cells and glomerular epithelium, not renal interstitium (Herzlinger et al.,
1992).Future study of the expression of the BF -2 transcription factor, a newly described
marker of immature renal stroma (Hatini et aI., 1996) would be helpful in further
discriminating, or linking, these two stromal tumors. Because CCSK and CMN sometimes
resemble other renal neoplasms, information gleaned from the further study of the
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histogenesis of these tumor types has implications for the proper diagnosis, and therefore,
treatment of these tumor types in the future. Further, the biological basis for the development
of the normal renal interstitium remains unknown. Therefore, the use of these stromal tumor
cultures may be useful in elucidating mechanisms of normal nephrogenesis as well.
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Figure 1. A, Northern analysis of genes relevant to normal nephrogenesis including tenascin-

C, WT-l, Pax-2, Pax-S, IGF-2, BP-2, and GAPD in CCSK primary tumor tissue. Tumor
specimens are noted above each lane of blots. A classical WT, Wll was included as a
positive control for WT-l, Pax-2 and Pax-So Hybridization with a GAPD cDNA fragment
was included to evaluate gel loading efficiency. B, Ethidium bromide stained gel of total
cellular RNA.
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Figure 2. A, Northern analysis of developmentally coordinated genes of nephrogenesis
including tenascin-C, WT-1, Pax-2, Pax-8, IGF -2, BP-2, and GAPD in a series of cellular
(ce) and classical (cl) CMN primary tumors. anaplastic Wilms' tumor W17 was included as
a positive control for WT-l, Pax-2, and Pax-8 mRNA. Hybridization with a GAPD cDNA
fragment was included to ensure for equal loading efficiency. B, Ethidium bromide stained
gel of total cellular RNA.
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Figure 3. Phase micrographs of untreated and atRA treated CCSK primary cell cultures. A,
phase micrograph of untreated CCSK-2 cells. B, CCSK-2 cells treated for 3 days with 1 JlM
atRA. C, Untreated CCSK-BG 1 cells. D, CCSK-BG 1 cells treated for 3 days with 1 JlM at
RA. Cells treated with atRA did not demonstrate marked differences at the light microscopic
level after 3 days of retinoic acid exposure. Although B and D demonstrate close cell
opposition in both CCSK cultures after atRA exposure, these findings were also found
focally in primary cell cultures not exposed to atRA. All micrographs at 200X.
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Figure 4. Phase micrographs of atRA and untreated CMN-l, CMN-2 and SK-N-SH
neuroblastoma cells. A, untreated SK-N-SH neuroblastoma cells; B, SK-N-SH cells treated
for 72 hours with 1 J.lM atRA; C, untreated cellular CMN-l cells; D, CMN-l cells treated
for 72 hours with 1 J.lM atRA; E, untreated cellular CMN-2 cells; F, CMN-2 cells treated for
72 hours with 1 J.lM atRA. A shows marked cellular clumping of SK-N-SH cells and
contrasts greatly with the differentiated phenotype (evidenced by the formation ofneurites)
in cells exposed to atRA for 72 hours (B). Arrows indicate neurite formation in B. There
were no microscopically evident changes visualized in atRA treated CMN-l cells (C&D) or
CMN-2 cells (E&F).All micrographs at 200X.
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Figure 5. TEM and SEM micrographs of untreated and atRA treated CCSK-2 primary cell
cultures. A, TEM micrograph of untreated CCSK-2 cells growing in multipile layers with
stromal morphology. B, TEM micrograph ofCCSK-2 cells exposed to 1 J,lM at RA for 72
hours. C, SEM micrograph of untreated CCSK-2 cells. D, SEM micrograph ofCCSK-2 cells
treated with 1J.lM atRA for 72 hours. TEM and SEM analysis reveals marked cellular
flattening in atRA treated cultures. TEM micrographs at 12,500X; SEM micrographs at
500X.
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Figure 6. TEM and SEM micrographs of untreated and atRA treated cellular CMN-1 cells.
A, TEM micrograph of untreated CMN-1 cells revealing multipile cell layers in culture. B,
TEM micrograph CMN-1 cells treated for 72 hours in 1 f.lM atRA revealing cellular
flattening and closer juxtaposition. C, SEM micrograph of untreated CMN-1 cells
demonstrating cellular disarray and multipile cell layers. D, SEM micrograph ofCMN-1 cells
exposed to 1 mM atRA for 72 hours showing interdigitation of tumor cells and cell
flattening. TEM micrographs at 12,500X ;SEM micrographs at 2,OOOX.
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Figure 7. A, Modulation of gene expression in atRA treated CCSK and SK-N-SH
neuroblastoma cell cultures. Cell lines evaluated are indicated at the top of the blots.
Numbers over each lane correspond to hours of exposure to atRA. Genes evaluated are noted
on the left of each blot. Three anaplastic Wilms' tumors W17, W4, and W16 were included
as controls for Pax-2, p53, and p21. Hybridization with a GAPD cDNA probe was included
as a indication of constitutive gene expression. B, ethidium bromide stained agarose gel of
total cellular RNA.
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Figure 8. Line graph demonstrating quantification ofPax-2, tenascin, p21, p53, and IGF-2
mRNA in CCSK-2 and SK-N-SH neuroblastoma cell cultures treated with atRA. Lines
representing gene expression are identified in a key to the right of the graph. A, Alterations
of gene expression in CCSK-2 cells exposed to atRA for a 48 hour period. B, Alterations of
gene expression in SK-N-SH neuroblastoma cells exposed to atRA over a 72 hour period.
Quantification was performed using Adobe Photoshop Version 4.0 software.
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Figure 9. A, Modulation of gene expression in atRA treated cellular CMN and SK-N-SH
neuroblastoma cell cultures. Cell lines evaluated are indicated at the top of the blots.
Numbers over each lane correspond to hours of atRA exposure. Genes which were evaluated
for RNA expression are noted at the left of each blot. Three anaplastic Wilms tumors, W17,
W4, and W16 were included as controls for Pax-2, p53, and p21. Hybridization with a
GAPD cDNA fragment was included to ensure equal loading of the gel. B, ethidiwn bromide
stained agarose gel containing total cellular RNA.
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Figure 10. Line graph demonstrating quantification ofPax-2, tenascin, p21, p53, IGF-2,and
IGF-BP2 mRNA in CMN-1 and SK-N-SH neuroblastoma cell cultures treated with atRA.
Lines representing gene expression are identified in a key to the right of the graph. A,
Alterations of gene expression in CMN-1 cells exposed to atRA for a 72 hour period. B,
Alterations of gene expression in SK-N-SH neuroblastoma cells exposed to atRA over a 72
hour period. Quantification was performed using Adobe Photoshop Version 4.0 software.
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Figure 11. Model of CCSK and CMN histogenesis during normal fetal kidney development.
A, the uninduced renal mesenchymal tissue which does not express the WT -1, Pax-2, Pax-8,
or tenascin genes. A tumorigenic event in these cells may lead to CCSK. B, Secondary
Mesenchyme destined to differentiate into elements of the renal interstitium. Cellular and
classical CMN may derive be derived from this tenascin expressing tissue. C, Condensed,
or induced renal mesenchyme which expressed WT -1, Pax-2, and Pax-8 during the inductive
process. This tissue forms elements of the renal tubular system.
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Chapter 6
Summary and Conclusions

The study of CCSK and CMN in the past has been difficult due to the rarity of these
tumor types and the inability of one research group to attain a sufficient number of these
tumors types for evaluation. This study reports, for the first time, the development of both an

in vivo and in vitro model system by which to study these rare renal neoplasms of childhood
in relation to Wilms' tumor and other pediatric malignancies.
Both cell cultures and nude mouse heterotransplants demonstrate similarities with their
respective primary tumor specimens when evaluated histologically!, ultrastructurally!' and
molecularly. Immunohistochemical characterization of cell lines has novelly demonstrated
SMA immunoreactivity in both CCSK cultures. The latter findings may suggest that CCSK is
a tumor derived from smooth muscle or a tumor which is derived from glomerular mesangial
cells of the kidney, as both are positive for the smooth muscle actin protein. Interestingly, SMA
immunoreactivity was limited to arterial smooth muscle cells in Carnoy's fixed paraffin
embedded CCSK primary tumor tissue. The latter suggests that the cell culture environment
(i.e. a collagen matrix) may have a differentiating effect upon CCSK cells. An origin in one
of these cell types is consistent with northern analysis data which has shown negativity for
markers of early induced mesenchyme such as WT -1, Pax-2 and Pax-8. Further, CCSK tumor
specimens demonstrated low levels oftenascin mRNA, a gene expressed only in the immature
stroma and renal interstitium of the kidney. In contrast, immunochemical findings in CMN are
consistent with their primitive mesenchymal origins and supportive of a histogenetic origin in
the early stromagenic cells. A panel of CMN primary tumor specimens expressed high levels
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oftenascin mRNA. The latter may be indicative a early stromagenic origin for this tumor type
and supports previous light and electron microscopic studies implicating fibroblasts and
myofibroblasts as the cell of origin for this tumor type. Like CCSK, CMN failed to
demonstrate mRNA for markers of induced mesenchyme and early epithelial progenitor cells
such as WT -1.
Due to the their similarity in histologic appearance, it has long been speculated that
CCSK and CMN may be linked in a tumor progression pathway (i.e. CMN may represent the
benign counterpart of the potentially aggressive CCSK). A similar association between
classical and anaplastic Wilms' tumors has suggested that the tumor suppressor protein, p53,
may be involved in progression. Karyotypic and immunohistochemical analysis of p53 has
suggested that this tumor suppressor may be involved in the pathogenesis of CCSK.
Immunohistochemical analysis of a large panel of CCSK and CMN in this study, however,
does not indicate that p53 is involved in CCSK pathogenesis. In fact, p53 immunoreactivity
was only demonstrated in cell cultures of the benign CMN and not in the CCSK cells,
contradictory to the supposed role of p53 in tumor progression. Further analysis of CCSK and
CMN cells using a DNA damage response assay confirms our previous immunohistochemical
findings in primary tumors that p53 is functional in these two tumor types. Functioning p53
molecules in CCSK suggests the possibility of another mechanism for the clinical
aggressiveness of this tumor type. Other mechanisms which might contribute to p53
dysfunction were also examined in this study. Pathologic overexpression of the p53 binding
protein, MDM-2, a protein which renders p53 inactive, was not present in a large panel of
CCSK, CMN, and Wilms' tumors. Even though the increased p53 protein stability in CMN
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cells remains unresolved, there may be several alternative explanations. For example, the cell
culture environment may cause an upregulation of p53 mRNA translation as a protective effect,
or p53 protein is rendered more stable due to a post-translational mechanism. Alternatively,
p53 protein stability might be associated with the presence of an as yet unidentified p53
binding protein in these cells. These two model cell lines may be useful in identifying such a
protein or proteins.
The functional analysis of p53 may also have prognostic utility as cells with mutations
are sometimes more sensitive to chemotherapeutic agents which render DNA damage such as
cisplatin and doxorubicin. Preliminary results in this laboratory have suggested that the
multi drug resistant anaplastic Wilms' tumor cell line W4, containing a p53 null genotype, is
particularly sensitive to cisplatin. The latter may be explained by the tumor cell's inability to
arrest and repair DNA damage. Thus, when enough damage has accumulated, cells will die.
The use of platinum agents (which are non-MDR drugs) in anaplastic tumors that are multidrug
resistant and p53 null may be clinically useful.
CCSK and CMN undoubtedly represent aberrations of normal kidney development as
children aged newborn through four years of age are most likely to be afflicted by this
neoplasm. The study of the in vivo and in vitro model of these tumor types has potential
usefulness in understanding normal nephrogenesis. The cellular and molecular mechanisms
for the development of the renal stromal interstitium remains relatively unexplored. The latter
contrasts greatly with the amount of information concerning the development of the renal
tubular cell system. Renal interstitial cells and renal mesangial cells only comprise a small
component of the normal adult kidney and their embryology remains unexplained. However,
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both of cell types are associated with significant pathologies. For example, pathological
deposition of extracellular matrix material is associated with glomerulosclerosis in disease
states such as diabetes mellitus and lupus erythematosus. Interestingly, immunohistochemical
analysis of CCSK cells in this study demonstrated smooth muscle actin positivity, a protein
which is expressed in normal human mesangial cells. Further, one of the hallmark histologic
features of CCSK is the deposition of collagenous extracellular matrix. Therefore, it follows
that CCSK may be a pathological proliferation of early, precursor mesangial cells. If so, CCSK
cell lines and tumor heterotransplants may be important models for better understanding the
mechanisms of abnormal extracellular matrix deposition in diabetic and autoimmune
compromised human mesangial cells. Therefore, in vitro and in vivo models of CCSK will be
useful in understanding the mechanisms of neoplasia in this tumor type as well as a potentially
useful

model

in the

study of renal

embryology,

diabetic

glomeruloscelerosis,

membranoproliferative glomerulonephritis, lupus nephritis, IgA nephropathy, as well as others.
Several additional experiments would continue to address the histogenesis of CCSK
and CMN and mechanisms of normal kidney development. Using our developed cell lines, cell
co-culture experiments including CMN cells and renal mesenchyme may provide evidence for
the origin of this tumor. That is, if CMN is truly of secondary mesenchymal origin, then
cultured tumor cells may express a soluble factor which orchestrates the development of renal
vesicles, and eventually normal tubular epithelium. Secondly, both CCSK and CMN cells
would be useful in transfection experiments. Several genes have important roles in the
mesenchymal to epithelial transformation of the kidney and include E-cadherin, ovumorulin,
hepatocyte growth factor, WT-l, Pax-2, and wnt-4. CCSK and CMN should be examined for
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their mRNA and protein expression of these genes. Furthermore, cellular transfection of these
genes may provide important clues for the origins of both tumor types. For example, would
Wilms' tumor-l transfection initiate epithelial differentiation ofCMN or CCSK tumor cells?
Lastly, tumor cells or xenografts derived from these tumor types should be treated with other
inducers of kidney development such as low concentrations of lithium. Or, more importantly,
these cells should be exposed to a biological inducer such as developing bone tissue to evaluate
morphological and molecular alterations.
More recent findings in the genetic control of normal kidney development may also
provide clues to the origins of pediatric renal tumors. For example, the BF-2 transcription
factor is expressed in early stromal cells and is thought to mediate their development in a
mouse model. A logical experiment would be to evaluate tumors which supposedly represent
aberrations of stromal development for defects in this gene. In BF -2 knockout mice, stromal
cells appear to develop normally, however, the kidney itself is smaller than normal, ducts have
limited branching, and fewer mesenchymal aggregates to differentiate. CCSK, CMN, and
Wilms' tumor, characterized by the apparent arrest of differentiation, may be a useful model
for the study ofBF-2 abnormalities. And, more importantly, CMN and CCSK cell lines will
hopefully provide tools for a more complete understanding of the molecular basis of normal
kidney development.
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